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SOMMARIO 
 
Introduzione   
Lo shock settico, altrimenti definito shock distributivo, è una complicanza 
della sepsi, caratterizzato da ipotensione marcata, con conseguente 
anomala distribuzione di sangue a vasi, organi e tessuti. Le alterazioni 
emodinamiche, cellulari e metaboliche descritte nei pazienti in shock settico 
portano ad una mortalità che è attualmente intorno al 40 %. I pazienti in 
shock settico sviluppano disfunzioni a più organi (MOF) ma i meccanismi 
molecolari che innescano il danno a livello dei tessuti sono ancora per la 
maggior parte sconosciuti e un trattamento specifico per lo shock settico non 
è ancora disponibile. 
 
Scopo 
Questo lavoro è parte del Progetto Europeo “ShockOmics”, uno studio 
multicentrico prospettico osservazionale, il cui obiettivo è identificare con un 
approccio multiscala, biomarkers molecolari nello scompenso cardiaco acuto 
in pazienti in shock settico.  
Lo scopo specifico del presente progetto di Ricerca è indagare le 
modificazioni indotte dallo shock settico sul profilo trascrizionale, utilizzando 
come sorgente di RNA le cellule del sangue. Questa indagine è svolta a più 
punti temporali a partire dall’ammissione del paziente all’unità di terapia 
intensiva (ICU). 
  
Materiali e Metodi 
I pazienti in shock settico sono stati reclutati nelle unità di terapia intensiva 
degli Ospedali Universitari di Ginevra e Bruxelles, partners del Progetto 
ShockOmics. I campioni di sangue sono stati raccolti all’ammissione del 
paziente alla ICU, che corrisponde alla fase acuta della malattia (T1), dopo 
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che il paziente ha ricevuto le terapie farmacologiche necessarie (T2) e allo 
stato stazionario (T3) che corrisponde al giorno 7 dal ricovero. L’RNA è stato 
estratto da sangue intero e i livelli di espressione di geni, RNA lunghi non 
codificanti e microRNA sono stati valutati con esperimenti di RNAseq. 
Abbiamo esplorato il dataset con l’analisi delle componenti principali (PCA) 
e il clustering gerarchico non supervisionato. Sono stati identificati geni e 
microRNA differenzialmente espressi. I processi biologici coinvolti nello 
shock sono stati studiati con un’analisi di ontologie geniche. I geni target di 
microRNA sono stati identificati con un metodo di predizione in silico. 
 
Risultati 
Abbiamo identificato due profili di espressione genica che corrispondono alla 
condizione acuta dello shock e allo stato stazionario. Confrontando la fase 
acuta dello shock (giorno 1) con la condizione di stato stazionario (giorno 7), 
abbiamo osservato  nei pazienti al giorno 7 la downregolazione di pathways 
della risposta immunitaria innata (recettori Toll-like e lectine di tipo C) e 
dell’infiammazione acuta (recettori delle interleukine di tipo 1 e allarmine) e 
l’upregolazione in questi pazienti di geni della risposta immune adattativa 
relativi all’attivazione di linfociti T e B. Abbiamo osservato una regolazione 
trascrizionale anche per geni con funzione antimicrobica, attività proteasica, 
geni coinvolti nel metabolismo dei carboidrati, nei pathways infiammatori 
lipidici, nel trasporto di vescicole e nella sintesi proteica. miR-125a-5p e miR-
150-5p, per i quali è stato predetto un ruolo regolatorio del pathway delle 
MAP chinasi, e miR-193a-3p sono stati identificati come differenzialmente 
espressi tra la condizione acuta e lo stato stazionario. 
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Conclusioni 
Abbiamo osservato una significativa modulazione trascrizionale di più classi 
di geni coinvolti nella risposta di difesa ai patogeni, nel sistema immunitario, 
nell’infiammazione e nel metabolismo. Questi risultati suggeriscono che nello 
shock settico viene indotta una rilevante modificazione del profilo 
trascrizionale nelle cellule del sangue conseguente alle alterazioni 
emodinamiche presenti nella condizione di shock e all’azione dei patogeni.   
Il profilo trascrizionale dei pazienti in shock circolatorio ha mostrato variabilità 
tra pazienti e ciò riflette la complessità della condizione di shock e della 
risposta individuale al trattamento. La combinazione dei dati clinici e del 
profilo di espressione genica potrebbe essere utile per identificare specifiche 
firme molecolari utili nella classificazione dei pazienti in shock settico. 
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ABSTRACT 
 
Introduction 
Septic shock, also defined as distributive shock, is a complication of sepsis, 
characterized by pronounced hypotension, followed by anomalous 
distribution of blood at vessels, organs and tissues. The hemodynamic, 
cellular and metabolic alterations described in septic shock patients lead to 
a mortality that is at present around 40%. Septic shock patients develop 
dysfunctions or failure to multiple organs (MOF) but the molecular 
mechanisms triggering tissue injury remain largely undetermined and a 
specific treatment for septic shock is still not available.  
 
Aim 
This work is part of the European Project ShockOmics, a multicentric, 
prospective, observational study, whose aim is to identify with a multiscale 
approach, molecular biomarkers in septic shock patients who develop acute 
heart failure. The specific aim of the present Research project is to 
investigate the modifications induced by septic shock on transcriptional 
profile, using blood cells as RNA source. This investigation is performed at 
different timepoints starting from admission of the patient to the intensive 
care unit (ICU). 
 
Materials and Methods 
Septic shock patients were recruited in the ICUs of Geneva and Bruxelles 
University Hospitals, that are Partners of ShockOmics Project. Blood 
samples were collected in the acute phase of the disease at ICU admission 
(T1), after the appropriate pharmacological intervention (T2 ) and at steady 
state  on day 7 of the ICU stay (T3). RNA was extracted from whole blood 
and RNA sequencing was used to evaluate the expression level of genes, 
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long non coding RNAs and microRNAs. We explored the dataset using PCA 
and unsupervised hierarchical clustering and we identified differentially 
expressed genes and microRNAs across conditions. Gene Ontology 
analysis was used to identify relevant biological processes involved in shock. 
We identified microRNA regulatory targets with an in silico target prediction.   
 
Results 
We identified two main gene expression profiles corresponding to the acute 
phase of shock and to the condition of steady state. Between the acute phase 
of shock (day 1) and the steady state condition (day 7) we observed in 
patients at day 7 a downregulation of pathways of the innate immune 
response (Toll-like receptor and C-type lectin receptors pathways) and of 
acute inflammation (IL-1 receptor family and alarmins) and the upregulation 
in the same patients of genes of the adaptive immunity related to B and T 
lymphocytes activation. A transcriptional regulation was observed also for 
genes with antimicrobial function and protease activity and for genes 
involved in carbohydrate metabolism, lipid inflammatory pathway, transport 
of vesicles and protein synthesis. miR-125a-5p and miR-150-5p, with a 
predicted regulatory role in the MAPK pathway, and miR-193a-3p were 
differentially expressed in the acute and steady state condition. 
 
Conclusion 
We observed a significant modulation of multiple classes of genes involved 
in defense response to pathogens, immunity, inflammation and metabolism. 
From these results it appears that in septic shock a relevant change in the 
transcriptomic profile of blood cells is induced, in order to counteract the 
pathogens and as a consequence of the hemodynamic changes underlying 
the circulatory failure. The transcriptomic profile of septic shock patients 
showed inter patient variability reflecting the complexity of the shock 
condition and of the individual response to treatment. Specific signatures 
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could turn out by combining clinical data and expression profile and could be 
used to better classify septic shock patients.  
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1 INTRODUCTION 
 
1.1 Sepsis and septic shock 
Sepsis is defined as a life-threatening organ dysfunction caused by a 
dysregulated host response to infection [1]. Sepsis accounts for one million 
cases annually in the United States and it is the most frequent cause of 
mortality in intensive care units (ICUs) [2]. Sepsis most often occurs in 
patients with underlying disabilities or illnesses and can originate from either 
bacterial or fungal or viral infection. The most common cause of sepsis are 
bacterial infections due to Gram-positive (52.1 %) or Gram-negative bacteria 
(37.6%), whereas fungal infections are less frequent (4.6%) but  they are 
increasing compared to the past [3]. Sepsis can arise from multiple kind of 
infection: Esper et al. reported that in the 25 year period from 1979 to 2003 
the most frequent types of infection in sepsis and septic shock were 
respiratory (33%), genitourinary (32%) or gastrointestinal (23%)  infections 
[4]. The identification of the causative organism can be missing in some 
patients and this is due to the fact that, by the time they are admitted to the 
ICU, they have already been treated with antibiotics[5]. 
Septic shock is a complication of sepsis in which underlying circulatory and 
cellular/metabolic abnormalities are profound enough to substantially 
increase mortality at 40% or more. The shock condition is characterized by 
pronounced hypotension, with systolic blood pressure <90mmHg or mean 
arterial pressure <65mmHg. Besides the specific antimicrobial therapy, 
patients are treated with vasopressors to maintain Mean Arterial Pressure > 
65mmHg. [1]. Hyperlactatemia is a common finding in septic shock patients 
and plasma lactate levels and their trend overtime are reliable markers of 
severity and mortality[6]. The majority of patients with shock develop multiple 
organ dysfunction syndrome (MODS), a condition in which organs not 
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directly affected by the original infection become dysfunctional. This 
ultimately represents the main cause of death[7].  
The course of sepsis is variable and often unpredictable and depends on 
factors such as age and pre-existing morbidities. Incidence rates for sepsis 
are known to increase with age[8], probably due to age-related differences 
in immune function, ranging from failed antigen processing by leukocytes[9] 
to altered inflammatory cytokine expression[10]. In sepsis, mortality depends 
on age and on the duration of the ICU stay: patients >55 years of age and 
those who remained in the ICU for >14 days have the highest post-discharge 
mortality rates. Mortality rates in septic shock also depends on expertise and 
experience of the treating center and range from 20 to 50 % depending on 
the country [11]. Only a minority of survived patients return to a normal life: 
survivors are frequently affected by cognitive dysfunction, neuropathies, 
myopathies, immunological dysfunction and other complications and they 
are at risk for early death within 5 years, with mortality rates as high as 
75%[12]. Possible reasons of these functional and physical declines might 
include ICU-acquired weakness owing to both inactivity and immobilization, 
as well as from inflammation, corticosteroid and neuromuscular blockers 
commonly used in sepsis treatment[13].  
 
1.2 Patient treatment in Intensive Care Unit 
In the treatment of sepsis the antimicrobial therapy is of primary importance: 
an initial appropriate antimicrobial therapy significantly reduces mortality risk 
and a broad spectrum of antimicrobial treatments covering all likely 
organisms should be started as soon as possible [14]. For what concerns the 
treatment of hypotension in septic shock, current therapies are targeted to 
restore an adequate level of perfusion in order to prevent organ failure: septic 
shock patients require the administration of fluids (crystalloids) and 
vasoactive agents (e.g. noradrenaline) in order to avoid prolonged 
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hypotension and they receive lung support with a ventilator in order to 
achieve adequate oxygenation. A crucial point is the protection of the heart 
and preservation of its function which is important to ensure hemodynamic 
stability and an adequate perfusion to all vital organs. In the ICU the severity 
of organ dysfunction can be assessed with a scoring system that quantifies 
disease severity according to clinical findings, laboratory data or therapeutic 
interventions. The predominant score in current use is the Sequential Organ 
Failure Assessment (SOFA)[15]. The score provides an assessment of the 
dysfunctions regarding liver, kidney, cardiovascular and central nervous 
system, respiration and coagulation and accounts for clinical interventions 
and laboratory variables like PaO2, platelet count, creatinine level, and 
bilirubin level. A higher SOFA score is associated with an increased mortality. 
 
1.3 Pathophysiology of sepsis 
In infection, the invading microbial pathogens are recognized by the host 
through pattern recognition receptors (PRRs). PRRs are expressed on innate 
immune cells such as polymorphonuclear neutrophils (PMNs), 
monocytes/macrophages and on epithelial and endothelial cells as well.  
PRRs recognize the presence of highly conserved and unique structures of 
microbial pathogens called pathogen-associated molecular patterns 
(PAMPs) as well as detect endogenous damage-associated molecular 
patterns (DAMPs) generated in the setting of cellular damage or tissue 
injury[16], [17].  
Examples of PAMPs are lipopolysaccharide (LPS) or lipid A, lipoteichoic acid 
(LTA), carbohydrate moieties, double-stranded RNA and unmethylated DNA 
motifs. At least five major classes of PRRs are known, which include two 
families of membrane-bound PRRs: Toll-like receptors (TLRs) and C-type 
lectin receptors (CLR), and three families of cytoplasmic PRRs: the 
nucleotide binding and oligomerization domain (NOD)-like receptors (NLRs), 
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retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and absence in 
melanoma 2 (Aim 2)-like receptors [18], [19]. Upon PAMP engagement, 
PRRs trigger a complex intracellular signaling system involving 
phosphorylation of mitogen-activated protein kinases (MAPKs), Janus 
kinases (JAKs), signal transducers and activators of transcription (STATs) 
and nuclear translocation of nuclear factor‑κΒ (NF-κΒ). Early response 
genes are expressed, including cytokines associated with inflammation 
(TNF, IL-1, IL-12, IL-18 and type I interferons (IFNs)) and the complement 
system is activated[13]. Monocytes/macrophages, PMNs and dendritic cells 
(DCs) can target pathogenic microorganisms through phagocytosis or by 
releasing substances such as inflammatory cytokines, chemokines, 
adhesion molecules, reactive oxygen species (ROS) and other mediators. 
The elimination of microbial pathogens from the host can result in an 
overwhelming inflammatory response, with the loss of normal immune 
homeostasis, which ultimately causes tissue damage and organ 
dysfunction[20]. As a form of protection, a period of immune hypo-
responsiveness, also known as endotoxin tolerance, can occur with repeated 
LPS stimulation and is associated with the reduced survival seen in patients 
with septic shock[21].  
Danger-associated molecular patterns (DAMPs, or alarmins) derived from 
host products within cells are sensed by retinoic acid inducible gene 1–like 
receptors (RLRs) and nucleotide-binding oligomerization domain-like 
receptors (NLRs), with promotion of the assembly of inflammasomes. 
DAMPs implicated in sepsis pathogenesis include high-mobility group 
protein B1 (HMGB1), S100 proteins, extracellular RNA, DNA, and histones.  
Inflammasome mediates the release of HMGB1, IL- 1b, and IL-18, which are 
secreted into the extracellular space and function to amplify the innate 
immune response ([22] and mediate pyroptosis, a form of programmed cell 
death.  
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The inflammatory response is a highly evolutionarily conserved system that 
is activated following a harmful stimulus like infection or injury and needs to 
be closely regulated. If the response exceeds a certain threshold, a systemic 
injury can occur. Reactive oxygen species (ROS) can damage cellular 
proteins, lipids and DNA and impair mitochondrial function, whereas the 
complement activation can further increase the generation of ROS, 
granulocyte enzyme release, endothelial permeability and tissue factor 
expression and may cause the death of adrenal medullary cells[23]. A 
profound effect is observed on coagulation and on the vascular and 
lymphatic endothelium where there is increased expression of selectins and 
adhesion molecules. The integrity of the endothelium is diminished due to 
neutrophils and platelets enhanced adhesion, to the release of inflammatory 
mediators and toxic oxidative and nitrosative intermediates. The response 
produced by sepsis enables platelets and leukocytes to reach tissue sites in 
response to trauma or localized infection, but the produced effect is so 
prolonged, excessive and generalized that it can lead to a considerable 
tissue injury. The endothelial dysfunction and the alterations of the glycocalix 
(a layer that covers the endothelium and supports the anticoagulant state 
and maintain tight junctions) promote coagulation characterized by 
microvascular thrombi, fibrin deposition, neutrophil extracellular trap 
formation. In sepsis and septic shock the leaky capillary membranes create 
massive loss of intravascular proteins and plasma fluids into the 
extravascular space. The vasodilation of the small blood vessels impairs the 
microcirculation resulting in a poor tissue perfusion. The widespread 
immunothrombosis can result in disseminated intravascular coagulation 
(DIC) with impairment of the microvasculature function and organ injury[24]. 
The interrelationship between inadequate oxygen delivery to peripheral 
tissues, ischemia and reperfusion injury in the organs, hemodynamic 
instability, inflammation and development of MODS has been extensively 
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investigated, but the molecular mechanisms which ultimately trigger tissue 
functional injury remain largely undetermined[25]. 
Sepsis can affect all organs of the body: patients often present decreased 
lung compliance with increased respiratory rate due to inflammatory-induced 
damage to alveolar capillary membranes with generation of pulmonary 
oedema. Myocardial depression is induced by mechanisms involving 
cytokines and nitric oxide or through cardiomyocytes injury induced by toxins, 
complement and DAMPs [Figure 1] [26].  
 
 
 
Figure 1 Management of myocardial dysfunction in septic shock. Prompt and 
adequate antibiotic therapy is important to decrease PAMPs arising from invasive 
microorganisms. Antibiotics Early goal-directed therapy (EGDT), including fluid 
resuscitation, vasopressor and inotropic therapy, and red blood cell transfusion, is 
important to re-establish organ perfusion pressure, which helps to maintain blood 
flow to tissues and reduces the release of damage-associated molecular patterns 
(DAMPs) in patients with septic shock [26].  
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The high levels of cytokines make the gut epithelium more permeable and 
the luminal content containing activated pancreatic proteases enzyme 
induces injury in the gut (autodigestion) and cause various degrees of cell 
and organ dysfunction that can reach the point of complete organ failure [27]. 
In the liver, sepsis impairs hepatocyte clearance of bilirubin and other crucial 
hepatic functions including the transport and processing of enteric pathogen 
lipids, further stimulating systemic inflammation[28]. In kidneys, cytokines 
and immune system mediate microvascular and tubular dysfunction resulting 
in acute kidney injury (AKI) [29] which is common in severe sepsis and 
increases the risk of death[30]. Severe sepsis patients typically present 
altered mental status with brain dysfunctions ranging from mildly impaired 
concentration to deep coma [31]. Systemic endothelial dysfunction 
compromises the blood-brain barrier, allowing inflammatory cytokines and 
cells to enter the brain, causing perivascular edema, oxidative stress, and 
neurotransmitter alterations. Areas of ischemia and hemorrhage can appear 
in the brain due to coagulopathy and impaired regulation of cerebral blood 
flow[32]. In addition the CNS is reached by a toxin influx due to hepatic and 
renal dysfunction.  
In sepsis the early proinflammatory state often develops into a later and 
prolonged state of immune system dysfunction. In septic patients, 
lymphocytes decrease their number and persisting lymphopenia after the 
onset of sepsis is a predictor of mortality[33]. Neutrophils acquire an 
immature phenotype with impaired phagocytosis[34] and myeloid-derived 
suppressor cell (MDSC) population is expanded[35]. Both immature blood 
neutrophils and MDSCs secrete anti-inflammatory cytokines, including IL‑10 
and transforming growth factor‑β (TGFβ), which further suppress immune 
function [Figure 2] [13]. Monocytes decrease the capacity to release 
proinflammatory cytokines such as TNF, IL‑1α, IL‑6 and IL‑12,  in response 
to LPS (endotoxin tolerance)[21]. LPS can still activate monocytes but they 
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are shifted towards the production of anti-inflammatory molecules such as 
IL-1 receptor antagonist (IL1-RA) and IL-10. Circulating antigen-presenting 
cells (APCs) lose the expression of the human leukocyte antigen-antigen D 
related (HLA-DR)[36] resulting in reduced antigen presentation and they 
increase the surface expression of inhibitory T cell ligands suppressing T cell 
function[35]. In response T cells skew their activation state to a 
immunosuppressive T helper 2 phenotype causing T cell anergy.   
In a post mortem study of sepsis patients, apoptotic cell death was identified 
as a main factor underlying immunosuppression with loss of T cells, B cells 
and dendritic cells. Accordingly,  a decrease of sepsis induced apoptosis, 
through pharmacological or genetic interventions, improve survival in animal 
models of sepsis[37]. Apoptosis of immune cells occurs in lymphoid tissues 
(spleen, thymus and lymph nodes) and gut-associated lymphoid tissues 
(GALTs)[38]. The damaging effects of apoptosis are not only due to the loss 
of immune cells but also to the impact that apoptotic cells have on the 
surviving immune cells. Uptake of apoptotic cells by monocytes, 
macrophages and dendritic cells induces immune tolerance, anergy or a T 
helper 2 (TH2) cell-associated immune phenotype[39], [40].  
Recent post-mortem studies have reported that a high number of patients 
who die of sepsis have unresolved opportunistic infections[41] due to a 
marked immunosuppression and during the course of the illness multiple 
viruses are often reactivated (cytomegalovirus, Epstein-Barr virus, herpes 
simplex virus)[42].  
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Figure 2 A) Theory 1: Cells of the innate immune system, including monocytes and 
neutrophils, release high levels of pro-inflammatory cytokines that drive inflammation 
(blue line; days 1–3). The intensity of the initial inflammatory response varies in 
individual patients depending on multiple factors, including pathogen load and 
virulence, patient co‑morbidities and host genetic factors. Early deaths in sepsis (top 
red line; day 3) are typically due to a hyperinflammatory ‘cytokine storm’ response 
with fever, refractory shock, acidosis and hypercatabolism. Most patients have a 
restoration of innate and adaptive immunity and survive the infection (recovery; blue 
and green lines; day 6). If sepsis persists, the failure of crucial elements of both the 
innate and the adaptive immune systems occurs such that patients enter a marked 
immunosuppressive state (blue and red lines; after day 6). Deaths are due to an 
inability of the patient to clear primary infections and the development of secondary 
infections. B) Theory 2: a competing theory of sepsis agrees that there is an early 
activation of innate immunity and a suppression of adaptive immunity; however, this 
theory holds that deaths in sepsis are due to the persistent activation of innate 
immunity that results in intractable inflammation and organ injury. According to this 
theory, late deaths in sepsis are due to persistent, underlying innate immune-driven 
inflammation[43]. 
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1.4 Metabolic dysfunction 
Patients with sepsis have damaged and dysfunctional mitochondria 
damaged by high levels of ROS[44]. At the cellular level a generalized 
reduction of energy expenditure is observed, which probably increases organ 
dysfunction as many viable cells reduce their efficiency in performing their 
specialized functions. This is involved in development of acute kidney injury, 
myocardial depression, hepatic dysfunction, encephalopathy, acute lung 
injury and decreased barrier and transport functions of the gastrointestinal 
tract [45]. Catabolism is another characteristic of severe sepsis. A 
prospective study of 63 critically ill patients in England documented rapid and 
substantial loss of muscle mass, especially in patients with multiorgan failure 
[46]. The breakdown of muscle tissue releases amino acids converted into 
glucose through the gluconeogenesis pathway which fuels the glucose 
dependent proliferation of innate immune cells. The insulin insensitivity and 
hyperglycemia characteristic of sepsis and critical illness may have evolved 
to ensure that glucose levels are adequate to support the massive immune 
response [47]. Serum lactate level is increased, which is considered a marker 
of cellular metabolic abnormality and a criteria to define septic shock. Other 
metabolic alterations reported in different settings of septic shock patients 
regard circulating kynurenine, fatty acids, lysophosphatidylcholines species 
and/or carnitine esters [48]–[50], pointing toward an overall derangement of 
energy circuits and lipid homeostasis. 
 
 
 
 
 
11 
 
1.5 Sepsis Biomarkers 
Biomarkers are molecular indicators that can be used for diagnosis or to 
predict the outcome. In biological homeostasis their measurement is in a 
reference window, consequently they are useful for identifying abnormal 
processes and are important factors in the decision-making process of 
disease assessment. Commonly used biomarkers for sepsis include C-
reactive protein (CRP) and procalcitonin (PCT), cytokines (tumor necrosis 
factor (TNF)-α, interleukin (IL)-1, IL-6, IL-10, osteopontin), chemokines 
(macrophage migration inhibitory factor (MIF), high-mobility-group box 1), 
and soluble receptors (soluble triggering receptor expressed on myeloid cells 
1 (sTREM-1), soluble urokinase-type plasminogen activator receptor 
(suPAR)) [51]. In clinical practice the use of a single biomarker doesn’t satisfy 
all requirements for sepsis diagnosis and treatment management because 
sepsis has a complex pathophysiology that involves hundreds of mediators.  
The use of emerging omics tools is particularly promising for complex and 
heterogeneous conditions such as septic shock. The systematic 
identification of sepsis biomarkers and examination of the molecular 
mechanisms underlying sepsis using omics approaches may provide 
insights into the physiological state of patients following infection. The use of 
multiple omics (i.e. transcriptomics, proteomics, metabolomics) could 
provide integrated information on particularly significant biomarkers, help to 
better understand the complex pathogenesis of the disease, its evolution and 
to develop tools for the effective diagnosis and to improve prognosis.  
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2 AIM OF THE WORK 
 
 
The aim of the present work, that has been performed in the frame of the 
European Project ShockOmics (HEALTH.2013.2.4.2-1), is to analyze the 
transcriptome of a cohort of 32 septic shock patients recruited in two 
Intensive Care Units (ICUs) in Europe at multiple timepoints of the clinical 
course. 
 
In detail we aimed to: 
 
 evaluate the blood gene expression at the time of ICU admission, at 
day 3 and day 7 of the ICU stay with RNA sequencing 
 
 apply the Principal Component Analysis and Unsupervised 
Hierarchical Clustering to explore the transcriptomic dataset 
 
 analyze the differential expression of protein coding transcripts, long 
non coding RNAs and microRNAs 
 
 identify biological processes and pathways modified during the 
clinical course of septic shock 
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3 MATERIALS AND METHODS 
 
3.1 Patient recruitment and inclusion criteria 
Septic shock (SS) patients were recruited in the Intensive Care Units (ICU) 
of two Clinical Centers, Hôpitaux Universitaires de Genève (Switzerland) and 
Hôpital Erasme, Université Libre de Bruxelles (Belgium).  
 
3.1.1 Inclusion criteria 
SS Patients included in the study were selected using the following criteria:  
 Septic Shock Severity: patients with SOFA > 5  
 First blood sample and first hemodynamic measurements available 
within 16 hours from admission to the ICU.  
 Informed Consent available: the consent is requested to the patient, 
or to its relatives in case of altered consciousness, and signed by the 
physicians in the ICU. Delayed consent may be asked according to 
local rules and regulations in case the relatives were unavailable at 
the time of potential enrollment. 
 
3.1.2 Exclusion criteria 
Patients were excluded from the study according to the following criteria: 
 Risk of fatal illness and death within 24 hours 
 Patients already enrolled in other studies 
 Active hematological malignancy or active cancer 
 Immunodepression: including transplant patients, patients positive to 
HIV virus; constitutive immune system deficiency, subministration of 
immunosuppressive therapy, including systemic corticosteroids 
(aerosols allowed). 
 Patients receiving plasma or whole blood  
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 Patients with pre-existing end stage renal disease needing renal 
replacement therapy (RRT), or chronically treated by intermittent 
dialysis.  
 Cardiac surgery in the previous ten days 
 Cirrhosis (Child-Pugh C) or acute liver failure 
 
 
3.1.3 Samples collection Timing guidelines 
The diagnosis of shock occurred either when patients are admitted to the 
ICU or after admission if they were previously admitted to the ICU without 
shock symptoms.  
 
Timing for the collection of blood samples for transcriptomics analysis [Figure 
3]:  
 Time 1 (Acute Shock): time at which the first blood sample for 
analysis is collected, within 16 h after ICU admission. This time point 
is considered representative of acute shock before the therapy has 
taken effect, when shock has already activated the main patho-
physiological cascades of inflammation and disease; 
 Time 2 (Post Treatment): time at which first blood sample is collected, 
at 48 h after ICU admission. At this time point, the treatment has been 
administered for a sufficient time to evaluate its effects on the early 
molecular markers of disease; 
 Time 3 (Steady State): time at which the third blood sample for 
analysis is collected, on day 7 of the ICU stay of the patient or before 
discharge from the ICU in case of shorter stays or before 
discontinuing therapy (death). At this time point, it is assumed that 
the molecular pathways previously affected by the pathological 
condition have reached a steady state. 
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Figure 3 Experimental scheme showing the timing of blood samples collection for 
transcriptomics analysis.  
 
 
3.1.4 Clinical data 
All the clinical data of each patient participating in the study are documented 
in the Case Report Form (CRF). Medical records were maintained 
anonymous using an alphanumeric hash code. All data collected in the CRFs 
were stored in a database and made available in tabular format. The clinical 
database shows patients at specific timepoints (rows) and clinical variables 
(columns).  
 
Clinical variables include records of:     
 demographics and comorbidities 
 blood pressure and heart rate 
 severity scores (SOFA, APACHE II at Time 1, 2, 3) 
 evaluation of Acute Heart Failure (AHF) assessed by a series of 
measures of cardiac function, cardiac output monitoring, lactate level 
and/or inotropic drugs weaning, velocity time integral (VTI) using 
echocardiography. 
 previous therapy 
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 temperature 
 on going therapy (drugs, fluids, etc…) 
 cardiorespiratory assistance (mechanical ventilation, extracorporeal 
membrane oxygenation, intra-aortic balloon pump, etc.) 
 biochemical parameters (creatinine, bilirubin, lactate, glycemia, 
complete blood count, coagulation markers, arterial blood gas 
analysis) 
 assessment of organ failure 
 cognitive assessment by Glasgow Coma Scale 
 survival in hospital, at 28 days and 100 days 
 
 
3.2 Laboratory protocols 
 
3.2.1 Blood collection and RNA extraction 
At timepoints T1, T2, T3, 1 ml of venous blood was collected from each 
patient in EDTA tubes and kept on ice. Immediately after, 400µl of whole 
blood were added to 400 µl of Denaturing solution (Ambion, USA), in 
duplicate. Total RNA was extracted from 800 µl of treated blood with MirVana 
Paris Kit (Ambion, USA). RNA was treated with TURBO DNA-free Kit 
(Ambion, USA) in order to remove any DNA contamination. RNA Quality 
Control was performed on all RNA samples with an electrophoretic run on 
Agilent Bioanalyzer instrument using the RNA 6000 Nano Kit (Agilent, Santa 
Clara, CA)[Figure 4]. RNA Integrity Number has been determined for every 
sample and all the samples were considered suitable for processing based 
on the RNA integrity (RIN > 7). RNA concentration was estimated through 
spectrophotometric measurement using a Nanoquant Infinite M200 
instrument (Tecan, Austria).  
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Figure 4 RNA quality control. Electrophoretic run on RNA6000Nano chip with Agilent 
Bioanalyzer. The RNA sample shows two peaks at 2000 nt and 4000 nt 
corresponding to ribosomal RNAs 18S and 28S. A strong signal corresponding to 
the smallRNA fraction is visible in the region between 25 nt (molecular marker) and 
200 nt. On the right the gel-like picture. 
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3.2.2 Library preparation for RNA sequencing 
Whole transcriptome sequencing libraries were prepared using the TruSeq 
Stranded Total RNA with Ribo-Zero Globin Kit (Illumina, San Diego, CA) 
using 800 ng of total RNA as input. The kit uses oligo-attached magnetic 
beads to remove rRNA and globin mRNA from total RNA. The remaining 
RNAs were purified, fragmented at 94°C for 8 minutes and primed with 
random hexamers for cDNA synthesis. Multiple indexing adapters were 
ligated to the ends of ds cDNAs that were then amplified with 11 PCR cycles. 
Final libraries were validated and quantified with the DNA1000 kit on Agilent 
Bioanalyzer Instrument [Figure 5]. Pooled libraries were sequenced on the 
HiSeq2500 Instrument producing 50x2 bp paired end reads.  
 
 
Figure 5 Library quality control. Electrophoretic run of a RNASeq library on DNA1000 
chip with Agilent Bioanalyzer showing a typical distribution skewed to the right. 
Molecular markers at 15 nt and 1500 nt. On the right the gel-like picture. 
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3.2.3 Library preparation for SmallRNA sequencing 
Small RNA sequencing libraries were prepared using the TruSeq SmallRNA 
Library Prep Kit (Illumina, San Diego, CA) using 500 ng of total RNA as input. 
Adapters were sequentially ligated to 3’ and 5’ of the RNA molecule and an 
RT reaction was used to create single stranded cDNA. The cDNA was then 
amplified with 8 PCR cycles using a common primer and a primer containing 
1 of 48 index sequences. After purification using Agencourt XP beads, 
libraries were validated and quantified with the High Sensitivity DNA kit on 
Agilent Bioanalyzer Instrument [Figure 6]. Indexed libraries were mixed 
according to their concentration in order to create an equimolar pool. The 
library pool was run in a polyacrylamide gel (Novex TBE gel 6%, Life 
Technologies) and the microRNA fraction was isolated with a gel cutter.  The 
final pooled library was validated with the High Sensitivity DNA kit on Agilent 
Bioanalyzer Instrument [Figure 7]  and sequenced on the NextSeq 
Instrument producing 50bp single end reads.   
 
Figure 6 Library quality control. Electrophoretic run of a SmallRNA library on High 
Sensitivity DNA chip. The library shows multiple peaks in the region up to 300 nt. 
The region of the highest peak (142 nt) corresponds to the typical size of a library 
fragment containing a miRNA insert. The insert length can be calculated subtracting 
the length of the adapter molecules (120 nt) from the fragment length estimated with 
the electrophoretic run. Molecular markers at 15 nt and 10380 nt. On the right the 
gel-like picture. 
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Figure 7 Library quality control. Electropherogram of a smallRNA library after size 
selection and enrichment for microRNA fragments. The estimated size of the library 
is around 145 nt corresponding to a insert size coherent with the expected length of 
miRNA molecules (20-26 nt). Molecular markers at 15 nt and 10380 nt. On the right 
the gel-like picture. 
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3.3 Sequencing data analysis 
In order to catch most of the shock transcriptomic features at molecular level, 
we performed RNA sequencing of whole transcriptome including mRNAs, 
long ncRNAs and small-RNAs (microRNAs). 
 
3.3.1 Transcriptomic data analysis workflow 
Whole blood RNA libraries were sequenced in six batches on HiSeq Illumina 
Platform. The bioinformatics workflow includes three core modules [Figure 
8]: 
 
 
1. A primary analysis which creates the counts matrix 
2. A secondary analysis that explores the transcriptomic dataset and 
identifies differentially expressed genes (DEGs) according to the 
experimental design 
•QC on raw reads
•Mapping to reference genome
• Post-Alignment Metrics
•Gene counts matrix generation
Primary 
Analysis
•Gene counts matrix processing 
and QC
• Identification of DEGs
• Transcriptomic profile analysis
•Data exploration (heatmap and 
clustering)
Secondary 
Analysis
•Overrepresentation analysis 
(ORA) from DEGs lists
• Pathways analysis
•Biological interpretation
Tertiary 
Analysis
Figura 1. Da aggiungere …. e 8 Analysis workflow for transcriptomic data  
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3. A ternary analysis that consists in bioinformatic downstream 
analyses, that starts from the identified list of DEGs and ends with the 
biological interpretation of the results. 
 
In the next paragraphs, methods and procedures of each part are described. 
 
3.3.1.1 Primary analysis 
The starting point of the analysis is the quality check of raw reads produced 
by the sequencing platform. Raw reads are stored in the FASTQ format. In 
this format, each read is described by four consecutive lines: sequence 
identifier, raw sequence (ATCG), + character line and corresponding quality 
score (ASCII encoding) of sequence read at 2nd line. Every sequenced 
sample comes with two FASTQ files corresponding to the two different 
strands (forward and reverse).  
We performed the quality control procedure using FASTQC (v11.2) in order 
to check several metrics, specifically focusing on the evaluation of base 
quality score distribution across reads length.  
 
3.3.1.1.1 RNASeq data 
Quality checked reads were mapped using STAR aligner (v2.5.2) using the 
GENCODE primary assembly genome as reference genome and the 
GENCODE evidence-based annotation of the human genome (GRCh38), 
version 24 (Ensembl 83). Mapping was setup in order to output only reads 
mapping uniquely to a single genomic coordinate. All reads mapping to 
multiple loci were discarded from downstream analysis. Once mapped, 
several post alignment metrics were performed in order to check coverage 
distribution across gene length, ribosomal RNA (rRNA) depletion efficiency, 
DNA contamination and number of genes detected. All these metrics were 
collected using RNAseq-QC software[52]. Samples failing post alignment 
quality control metrics were resequenced. The primary analysis ends with 
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genes counts matrix creation. This step is fundamental to quantitatively 
determine how many fragments (reads pair) cover each single gene. 
Counting is not a trivial operation because mapped reads can be splitted over 
two or more exons or can overlap more than one gene. This process was 
performed using featurecounts module implemented in the subread 
software[53]. Parameters were setup accordingly, in order to count only 
fragments that map unambiguously to a single gene and taking into account 
strand information. 
 
3.3.1.1.2 SmallRNA sequencing data 
FASTQ files were converted into FASTA files and adapter sequences were 
removed using perl scripts. Sequences of 2588 human mature microRNAs 
were downloaded from miRBase 21 database. Only reads perfectly matching  
miRBase microRNA sequences were considered and used to produce count 
expression values.  
 
3.3.1.2 Secondary analysis 
The second step of the bioinformatics analysis was centered on the study of 
the transcriptomic profiles and on the identification of differentially expressed 
genes (DEGs) by comparing different conditions according to the 
experimental design. Gene counts matrix was mainly processed and 
analyzed by using DESeq2 R package[54].  
 
3.3.1.2.1 DESeq2 theory 
DESeq2 suite offers a general solution for gene-level analysis of RNA-Seq 
data. DESeq2 performs well both in experiments with a small number of 
samples and with many samples. The DESeq2 models read counts 𝐾𝑖𝑗 as 
following a Negative Binomial distribution with mean 𝜇𝑖𝑗 and dispersion 𝛼𝑖. 
Terms are modelled through a generalized linear model (GLM) of the form: 
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𝐾𝑖𝑗  ~ 𝑁𝐵 (𝑚𝑒𝑎𝑛 = 𝜇𝑖𝑗  , dispersion =  𝛼𝑖𝑗  )  
 
In the count matrix 𝐾 each row i represent a gene, whereas at column j there 
are the samples. Hence, 𝐾𝑖𝑗 indicates the number of unique unambiguously 
mapped reads that map to the gene i in sample j. The NB distribution has 
mean 𝜇𝑖𝑗, which is the quantity 𝑞𝑖𝑗 that is proportional to the cDNA 
concentration in the library scaled by a normalization factor 𝑠𝑖𝑗 which takes 
into account the total amount of cDNA sequenced in the sample j. In formula 
the mean of the NB for the gene i and sample j is: 
𝜇𝑖𝑗 = 𝑠𝑖𝑗 ∗ 𝑞𝑖𝑗 
 
The purpose of the size factors 𝑠𝑗 is to render counts from different samples, 
which may have been sequenced to different depths, comparable. Hence, 
the ratios 𝐸𝐾𝑖𝑗 𝐸𝐾𝑖𝑗′⁄  of expected counts for the same gene i in different 
samples j and j′ should be equal to the size ratio 𝑠𝑗 𝑠𝑗′⁄  if gene i is not 
differentially expressed or samples j and j′ are replicates. The total number 
of reads, ∑ 𝐾𝑖𝑗𝑖  could be a good measure of sequencing depth and hence a 
reasonable choice for 𝑠𝑗. Experience with real data, however, shows this not 
always to be the case, because a few highly and differentially expressed 
genes may have strong influence on the total read count, causing the ratio 
of total read counts not to be a good estimate for the ratio of expected counts. 
Size factors are then estimated using the median-of-ratios method. This 
method relies on the creation of a reference pseudosample in which gene by 
gene the value of expression for the each gene is the geometric mean of the 
counts of all samples in that gene. Hence, the size factors vector results as 
the median (across all genes) of the ratios between observed counts and the 
value of the pseudocount of each sample. One size factor for sample. In 
formula: 
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?̂?𝑗 =  
𝑚𝑒𝑑𝑖𝑎𝑛
𝑖
∗  
𝑘𝑖𝑣
(∏ 𝑘𝑖𝑣
𝑚
𝑣=1 )
1
𝑚
  
The coefficients 𝛽𝑖 give the 𝑙𝑜𝑔2 fold changes for gene i for each column of 
the model matrix X. 
 
𝑙𝑜𝑔2(𝑞𝑖𝑗) =  𝑥𝑗 𝛽𝑖 
The second parameter needed in the algorithm is the coefficient of dispersion 
𝛼𝑖. This coefficient describes the relationship between the variance of the 
observed count and its mean value:  
 
𝑉𝑎𝑟 𝐾𝑖𝑗 =  𝜇𝑖𝑗 + 𝛼𝑖𝜇𝑖𝑗
2  
 
The 𝑙𝑜𝑔2 fold changes in 𝛽𝑖 are the maximum a posteriori estimates after 
incorporating a zero-centered Normal prior providing a moderated 𝑙𝑜𝑔2 fold 
change estimates. Dispersions are estimated using expected mean values 
from the maximum likelihood estimate of 𝑙𝑜𝑔2 fold changes, and optimizing 
the Cox-Reid adjusted profile likelihood. 
The steps performed by the DESeq2 are the following: 
 
1. estimation of size factors 𝑠𝑗 by estimateSizeFactors 
2. estimation of dispersion 𝛼𝑖 by estimateDispersions 
3. negative binomial GLM fitting for 𝛽𝑖 and Wald statistics by 
nbinomWaldTest or Likelihood Ratio Test 
 
3.3.1.2.2 Data transformation 
 
In order to analyze and explore expression data by clustering and principal 
components analysis techniques is necessary to transform data. Typically, 
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in RNA-Seq data are heteroskedastic that is the variance grows with the 
mean. Common statistical methods for exploratory analysis of 
multidimensional data, especially methods for clustering and ordination (e.g., 
principal-component analysis), work best for (at least approximately) 
homoscedastic data; this means that the variance of an observable quantity 
(i.e., here, the expression strength of a gene) does not depend on the mean. 
For example, if PCA is performed directly on a matrix of normalized read 
counts, the result typically depends only on the few most strongly expressed 
genes because they show the largest absolute differences between samples. 
A simple and often used strategy to avoid this is to take the logarithm of the 
normalized count values plus a small pseudocount (log2(normcounts) + 1). 
In this situation, however, genes with low counts tend to dominate the results 
because, due to the strong Poisson noise inherent to small count values, 
they show the strongest relative differences between samples. To avoid that 
a few highly variable genes dominate the distance measure, and have a 
roughly equal contribution from all genes, we used the regularized log-
transformation (rlog) that stabilize the variance of the data and make its 
distribution roughly symmetric and suitable for exploratory analysis. The rlog 
transformation at high counts is pretty equal to an ordinary log2 
transformation but at low counts stabilizes the variance. 
 
3.3.1.2.3 PCA Analysis 
 
Principal Component Analysis was performed using the plotPCA function in 
deseq2 package. The function is a wrapper function that call prcomp function 
on deseq2 transformed data. PCA was performed using top 5000 most 
variable genes from the regularized log transformed object. 2D PCA plots 
were generated showing the percentage of variability explained by the 1st 
and the 2nd components. Patients were colored by the time point variable.  
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3.3.1.2.4 Heatmap generation 
 
In order to view and explore the transcriptional signature that allow to 
discriminate group of patients, we used heatmap plot. Heatmap plot is a 
graphical representation of data where the individual values contained in a 
matrix are represented as colors. Rows represent genes, whereas columns 
represent samples. The color of the tile Tij represents the z-score of the 
expression values distribution for sample i at gene j. Every gene has its own 
distribution. The data from which the heatmap is drawn is the matrix of log2 
normalized counts plus 1 in order to avoid missing values for log2 values less 
than 1. Normalized counts matrix is calculated using median of ratios method 
as previously explained. 
 
𝑙𝑜𝑔2(𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑐𝑜𝑢𝑛𝑡𝑠 + 1) 
 
In particular, pheatmap function was used to create all the heatmaps. Using 
rlog counts instead of log2(normalized counts + 1) is not necessary in this 
approach because low counts values tend to be absent in differentially 
expressed genes list. All heatmaps were drawn organizing tiles using 
hierarchical clustering at sample / patient level. In this way is possible to 
easily identify which group of genes allow to discriminate transcriptomics 
profiles at sample level. By using also hierarchical clustering to organize tiles 
on the heatmap the user can instead identify more clearly which are the 
group of genes that share the same expression signature across samples 
investigated. Note that hierarchical clustering at sample level (columns) is 
not affected by enabling hierarchical clustering at gene level (rows). Briefly 
the hierarchical clustering was setup using Euclidean distance as method to 
create distances matrix and complete method as the aggregation method for 
clustering.  
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3.3.1.2.5 Differential expression analysis 
Differential expression analysis was performed using a two-stage procedure. 
The first stage aimed to identify genes whose expression changes across 
timepoints, in order to identify the genes that can potentially  characterize the 
severity of a specific timepoint. The second stage focuses on identifying 
differentially expressed genes between extreme conditions, acute phase 
(T1) and recovery phase (T3). First-stage DEGs analysis aims to answer the 
following question: which are the genes that significantly change their 
expression across time, considering that for each sample all three timepoints 
are available? To answer this question, we performed the DEGs analysis 
using the nbinomLRT function implemented in deseq2 package. This 
function tests for significance of change in deviance between a full and 
reduced model.  
Full model is represented by the following design formula: 
 
~ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 + 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡 
 
With this formula, we model counts taking care of patient and timepoint. 
Reduced model is instead described by this one: 
 
~ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 
 
As we can see in the reduced model, the timepoint variable is not present 
anymore. In this way we model counts taking care only on the sample 
variable, that is equal to say that time does not contribute to model counts.  
The difference in deviance is compared to a chi-squared distribution with 
degrees of freedom = (reduced residual degrees of freedom - full residual 
degrees of freedom).  
If a difference is present between two models, means that full model, and 
hence the fitting of timepoint variable on the negative binomial model can 
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significantly and statistically explain differences based on timepoint variable. 
The second stage of the DEGs analysis was performed by the 
nbinomWaldTest function that use the default test implemented in the 
deseq2, the Wald test. This function tests for significance of coefficients (log2 
fold changes) in the Negative Binomial GLM, using previously calculated size 
factors and dispersion estimates, as stated above in the deseq2 theory 
paragraph. The second stage aimed to identify differentially expressed 
genes between acute phase (T1) and steady state phase (T3) taking into 
consideration the patient variable. Taking into consideration patient variable 
in the fitting of counts is fundamental because allow to taking into 
consideration the absolute patient-specific signature at ICU admission. In this 
way, we can force to say that DEGs between acute and recover conditions 
are “normalized” for patient specific variability. Conditions T1 and T3 in the 
second stage analysis are not characterized by the same samples as in the 
first-stage analysis. We indeed remove outlier samples that do not map into 
the main signature of T1 and T3 samples. The steps performed in the 
removal of these samples are described in the results chapter. P-value 
primary threshold for both LRT and Wald-Test was set to 0.01.  
 
3.3.1.3 Ternary Analysis 
 
3.3.1.3.1 Volcano plot  
Volcano plot is a type of scatter-plot useful for the representation of results 
of -omics experiments. A volcano plot combines a measure of statistical 
significance from a statistical test (p value) with the magnitude of the change, 
enabling quick visual identification of those genes that display large 
magnitude changes between two conditions and that are also statistically 
significant. A volcano plot is constructed by plotting the negative log10 of the 
p value on the y axis and the log2foldchange between the two conditions on 
the x axis. This results in genes with low p values (highly significant) 
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appearing toward the top of the plot, whereas genes with highly positive fold 
change appear in the extreme right of the plot and genes with highly negative 
fold change in the extreme left of the plot. Volcano plots were created in R 
using ggplot2 package. 
 
3.3.1.3.2 Gene Ontology analysis 
Gene Ontology (GO) analysis was performed using the web tool DAVID 
6.8[55] with a Gene Ontology database updated to the release of Apr 2016. 
DAVID website offer a Functional Annotation Tool useful to perform a GO 
term enrichment analysis to highlight the most relevant GO terms associated 
with a given gene list. The GO analysis was performed on biological 
processes, molecular function and cellular components. DAVID requires as 
input a list of genes (in our case the list of differentially expressed genes) and 
performs an overrepresentation analysis in order to identify in the input list 
GO terms including a significantly higher number of genes compared to the 
expected value according to the background genome. The statistical test 
used in DAVID is the EASE score, a modified and more conservative Fisher 
Exact Test. GO terms with a Benjamini adjusted p-value < 0.1 were 
considered significantly enriched. For each GO term the fold enrichment 
value, measuring the level of enrichment, was reported. With a manually 
curated analysis GO terms were clustered in 5 functional groups and 
redundant GO terms were removed. 
 
3.3.1.3.3 Target prediction 
Analysis of microRNA targets was done with TargetScan7.1 database. 
TargetScan predicts biological targets of miRNAs by searching for the 
presence of conserved 8mer, 7mer, and 6mer sites that match the seed 
region of each miRNA[56]. In mammals, predictions are ranked based on the 
predicted efficacy of targeting as calculated using cumulative weighted 
context++ scores of the sites[57]. As an option, predictions are also ranked 
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by their probability of conserved targeting[58]. TargetScanHuman considers 
matches to human 3' UTRs and their orthologs, as defined by UCSC whole-
genome alignments.  
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4 RESULTS 
 
4.1 Cohort description 
 
A total of 32 SS patients are included in the present work. Patients have an 
average age of 65 years and there is a moderate prevalence of males. They 
are slightly overweight, with an average Body Mass Index (BMI) of 26. 
Mortality rate is about 30% reflecting the condition of critical illness of septic 
shock patients. The severity of disease was measured at ICU admission 
using the APACHE II score (“Acute Physiology and Chronic Health 
Evaluation II"). The level of organ dysfunction was assessed with the SOFA 
score (Sequential Organ Failure Assessment score) in order to track the 
patient status during the stay in the ICU [Table 1]. 
 
  
  Septic shock (n=32) 
Age 65.91 ± 18.71 
Male sex 21 (65%) 
BMI 26.04 ± 5.47 
APACHE II 32.65 ± 7.55 
SOFA   12.55 ± 2.72 
Hospital mortality (n) 10 (31%) 
Mortality 28 days (n) 10 (31%) 
  
Table 1 Clinical characteristics (mean ± stdev) of the 32 septic shock patients 
included in the present study. 
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Three main sites of infection were identified corresponding to: infections of 
the respiratory system, of the urinary tract and abdominal infections [Figure 
9]. The infective agent was identified through blood cultures or additional 
sampling in the site of infection. In 14 patients a unique pathogen  was 
identified (unimicrobial infection), whereas in 12 patients more than one 
infective agent was isolated (polymicrobial infection). Overall, in the cohort 
different kind of pathogens were identified ranging from bacteria to fungi and 
viral agents [Figure 9]. In 6 patients it was not possible to identify the 
infectious agents using microbial cultures.  
 
 
 
 
 
 
 
Table 2 shows the clinical characteristics of the patients at the three 
timepoints. A significant variation across time (p < 0.01) was observed for 9 
clinical variables [Table 2]. As expected, septic shock is characterized by 
persistent hypotension, as shown by the significant decrease of systolic, 
diastolic and mean arterial pressure (MAP) at day 1, that tend to increase 
overtime. The clotting tendency of blood (prothrombin measurement) was 
higher at admission and it diminished later. Lactate, which is a product of the 
anaerobic metabolism and an important marker in shock, was detected at 
higher levels during the acute phase of shock (day 1) and diminished after 
therapies (day 3 and day 7). SOFA score showed a higher degree of organ 
a b 
Figure 9 a) Pie chart showing the body part interested by infection b) Pie chart 
showing the types of infective agents identified through cultures. Data expressed in 
percentage referred to the 32 SS patients. 
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dysfunction at ICU admission compared to the later timepoints. Death 
occurred in 10 patients out of 32 at 28 days from ICU admission. 
 
 
Clinical variable Day 1 Day 3 Day 7 p-value 
Systolic (mmHg) 85.18 ± 12.34 94.76 ± 14.51 111.3 ± 22.3 1.449E-05 
Diastolic (mmHg) 45.18 ± 6.27 50.73 ± 8.90 55.52 ± 12.43 0.002081 
MAP (mmHg) 58.18 ± 6.10 65.03 ± 8.56 73.78 ± 14.00 5.809E-06 
Heart Rate (bpm) 106.4 ± 25.3 94.46 ± 23.19 102.9 ± 21.1 n.s. 
Na 138.5 ± 5.7 141.2 ± 4.6 142.9 ± 5.6 n.s. 
K 4.26 ± 0.87 4.06 ± 0.41 4.02 ± 0.42 n.s. 
Prothrombin 1.38 ± 0.37 1.16 ± 0.23 1.11 ± 0.24 0.0004122 
pH 7.29 ± 0.10 7.40 ± 0.07 7.46 ± 0.04 6.064E-08 
PaO2 92.45 ± 38.52 73.46 ± 15.80 77.16 ± 20.25 n.s. 
PaCO2 38.36 ± 9.99 38.46 ± 8.31 37.68 ± 8.06 n.s. 
Glasgow 6.27 ± 4.42 9.84 ± 4.19 11.73 ± 4.02 0.0001084 
Hematocrite 33.49 ± 5.56 30.70 ± 4.92 31.35 ± 4.55 n.s. 
Leukocytes 16.85 ± 12.30 15.39 ± 9.06 13.92 ± 5.70 n.s. 
Platelets 169.1 ± 103.4 158.2 ± 87.2 237.7 ± 122.3 n.s. 
Creatinine 1.91 ± 1.24 1.32 ± 1.00 1.01 ± 0.59 0.0007856 
Bilirubin 2.63 ± 4.91 2.32 ± 6.19 1.92 ± 4.40 n.s. 
Glycemia 170.2 ± 77.0 142.8 ± 40.1 130.1 ± 34.5 n.s. 
Lactate 4.90 ± 2.40 1.56 ± 0.73 1.36 ± 0.68 2.271E-10 
SOFA 12.59 ± 2.68 9.57 ± 2.77 7.88 ± 3.00 2.372E-06 
     
Table 2 Clinical characteristics of 32 septic shock patients at three timepoints (mean 
± SD). P-values obtained with a Kruskal-Wallis Test. n.s. = not significant.   
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4.2 Transcriptomic experiment (RNAseq) 
 
The transcriptomic dataset includes 78 biological samples collected in 32 
shock patients. Gene expression profiling is available for 32 patients at day 
1 (T1), for 26 patients at day 3 (T2) and for 20 patients at day 7 (T3). On 
average, 29.85 ± 6.74 million fragments per sample were sequenced. 64.37 
± 8.10 % of fragments mapped uniquely to the reference genome Hg38 and 
48.23 ± 6.51 % million fragment counts per sample mapped uniquely and 
unambiguously to the Human GENCODE reference annotation file. The 
library preparation used in this study allows to analyze the whole 
transcriptome. The amount of reads produced was in line with the 
recommendations from the ENCODE consortium for  differential expression 
analysis.  
 
 
4.2.1 Data exploration of septic shock at three timepoints 
 
We used Principal Component Analysis (PCA) to describe and explore the 
normalized gene counts dataset [Figure 10]. The PCA plot showed that 
biological samples are roughly clustered according to their timepoint: 
samples at T1 are mainly in the left part of the plot, whereas T2 samples are 
plotted in the central part and T3 samples in the right part of the graph. An 
ANOVA test on the PC1 of the three groups (T1,T2,T3) confirmed that there 
is a significant difference at gene expression level between the three 
timepoints (p-value 1.62e-10). Tukey multiple comparisons of means test 
showed a significant difference between each timepoint (p-value < 0.005 in 
each comparison).  
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Figure 10 PCA of 32 SS patients at multiple timepoints based on the top 5000 
variable genes. PC1 and PC2 of each biological sample are shown in a two-
dimensional plot. Different colors are used to identify samples at different timepoints 
according to the legend. 
 
A subset of the dataset including 17 patients with all three timepoints was 
used to perform differential expression across time. Likelyhood ratio test 
(LRT) (general linear model) identified 5175 transcripts showing a significant 
modulation of their expression across the 3 timepoints (FDR < 0.01). For 
downstream analysis the list of transcripts has been restricted using more 
stringent filtering based on expression level and statistical significance 
(baseMean > 20 and FDR < 0.00001). The final list included 1748 
differentially expressed genes (DEGs) belonging to different categories. 
Gene expression data of the 1748 DEGs in the 17 patients were represented 
in a heat map [Figure 11]. The unsupervised hierarchical clustering identified 
two groups of samples in the dataset. Group A with a majority of patients at 
T3  (day 7) and group B with a majority of patients at T1 (day 1).The two 
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groups show distinct transcriptomic profiles at the 1748 genes. [Table 3]. 
Samples at T2, on the contrary, can be found in both branches of the 
condition tree showing a high inter-patient variability at this timepoint that 
likely reflects the individual variable response to treatment observed by 
clinicians. The transcriptomic profile of two patients (E17, E32) at T1 clusters 
in group A, showing that these patients at T1 are more similar to patients at 
T3. One patient (G08) had all three timepoints in group B, showing a lack of 
improvement of the clinical condition from T1 to T3.  
 
Group A Group B 
Figure 11. Unsupervised hierarchical clustering of 17 SS patients (analyzed at 3 
timepoints) and 1748 genes differentially expressed during time. Clustering of genes 
(rows) and biological samples (columns) was based on Euclidean distance.  Heatmap 
colors (purple and green) are based on normalized gene counts expressed in 
logarithmic scale.  A color code was used to highlight the timepoints (red=T1, 
green=T2, blue=T3). 
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Condition Group A (n) Group B (n) 
T1 2 15 
T2 8 9 
T3 16 1 
 
Table 3 Abundance of samples in Group A and Group B according to the timepoints. 
 
 
 
4.2.2 Data exploration of transcriptomic profiles in the whole 
cohort 
 
All the available samples at condition T1 (32 patients) were clustered based 
on the signature composed of 1748 genes. We also included in the analysis 
as controls (CT), blood samples collected at day 1 from 7 septic patients who 
didn’t develop shock. 
 
 
  Septic shock (n=32) Sepsis (n=7) p-value 
Age 65.91 ± 18.71 67.43 ± 11.46 n.s. 
Male sex 21 (65%) 4 (57%) n.s. 
BMI 26.04 ± 5.47 20.83 ± 6.49 0.0386 
APACHE II 32.65 ± 7.55 21.57 ± 4.50 0.0009 
SOFA  12.55 ± 2.72 9.29 ± 3.09 0.0184 
Hospital mortality 10 (31%) 0 (0%) n.s. 
Mortality 28 days 10 (31%) 0 (0%) n.s. 
 
Table 4 Clinical characteristics of septic shock patients compared to sepsis patients 
used as controls (mean ± SD). P-values obtained with a Wilcoxon Rank Sum Test. 
n.s. = not significant.   
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Group A Group B 
 
Figure 12 Unsupervised hierarchical clustering of 32 septic shock patients and 7 
septic controls at day 1 with a selection of 1748 genes. A color code was used to 
highlight SS patients and septic controls (red=Septic shock, blue=Septic control). 
 
The dendrogram divides the dataset in two groups. Branch A contains 12 
patients (6 sepsis controls and 6 SS patients). Branch B contains 26 septic 
shock patients and 1 septic control. Septic shock patients in group A show 
an expression pattern similar to septic controls and different from the other 
septic shock patients, showing that a wide variability can be observed at the 
molecular level among septic shock patients.  
 
Condition Group A Group B 
Septic shock 6 26 
Sepsis control (CT) 6 1 
   
Table 5  Abundance of samples in Group A and Group B according to the condition. 
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4.2.3 Differential expression analysis: acute phase vs steady 
state  
 
The analysis of gene expression across three timepoints discussed above 
has identified timepoints T1 and T3 as the most significantly different both on 
a clinical and on a molecular basis.  We then performed an additional  
analysis comparing gene expression between T1 and T3 in order to highlight 
the genes modified during the transition from the acute phase of shock to the 
steady state. Moreover, based on the heatmaps [Figure 11, Figure 12] we 
decided to discard 4 SS patients (E17, E32, G28 and G08) because the 
clusterization of their timepoints was different from that of the majority of 
patients. Principal Component Analysis (PCA) shows that patients selected 
for analysis at T1 and T3, are completely separated based on the first 
principal component [Figure 13].  
 
Figure 13 PCA analysis on the 5000 most variable genes in a dataset of 13 septic 
shock patients. PC1 and PC2 of each biological sample are shown in a two-
dimensional plot. Different colors are used to identify samples at different timepoints 
according to the legend.  
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Septic shock patients analyzed at T1 and T3 (n=13) 
Age 63.07 ± 21.48 
Male sex 10 (76.92%) 
BMI 27.82 ± 6.41 
APACHE II 32.38 ± 9.30 
SOFA  T1 12.15 ± 1.95 
SOFA T3 7.33 ± 2.38 
Hospital mortality (n) 2 (15.38%) 
Mortality 28 days (n) 2 (15.38%) 
  
Table 6 Clinical characteristics of 13 septic shock patients analyzed in the acute 
phase and the steady state of shock (mean ± SD). 
 
 
As shown in Table 6, the 13 patients analyzed were homogeneous for two 
parameters (APACHE II and SOFA T1) that characterized the shock 
condition at admission and for SOFA at T3. The majority of the patients are 
males and mortality affected 2 patients out of 13. The age was 
heterogeneous including patients from 25 to 86 years.   
Differential expression analysis identified 4842 genes modulated between T1 
and T3 (FDR < 0.01). For downstream analysis the list of transcripts has 
been narrowed using more stringent filtering based on expression level and 
statistical significance (baseMean > 20 and (FDR < 0.00001 or |logFC| >1)). 
We reduced the list to 1981 DEGs with 789 upregulated and 1192 
downregulated genes [Figure 14, Table 7].  
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Figure 14 Volcano plot of the comparison between T1 and T3. The plot shows fold 
change and FDR in logarithmic scale of 4842 differentially expressed genes. Blue 
color identifies 1981 DEGs passing the filter of log2FC and FDR values. 
 
 
 
Transcript category  Abundance 
protein coding 1791 
lincRNA 37 
antisense RNA 38 
pseudogene 30 
other RNAs  85 
  
Table 7 Description of differentially expressed genes between day 1 and day 7 based 
on the transcript category.  
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4.2.4 Pathway analysis 
 
The list with 1981 differentially expressed genes (DEGs) has been analyzed 
with DAVID 6.8 functional annotation tool to identify overrepresented 
biological processes, molecular functions and cellular components. 
Significant ontology terms were selected using a p-value threshold 
(Benjamini adjusted p-value < 0.1) and they were clustered in functional 
macro groups with a curated procedure [Table 8][Appendix:Table 13,Table 
14]. The groups identified are related to the functions of the immune systems, 
inflammation, innate and adaptive immune response. A group of ontology 
terms related to protein synthesis and  transport of vesicles was also 
identified [Figure 15]. 
 
  
Figure 15 Bar plot showing the number of differentially expressed genes in each 
ontology macro group. Counts are referred to genes belonging to GO terms of the 
category of Biological Processes (BP).  
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Table 8 Gene Ontology analysis results. The table reports enriched GO terms (BP, MF, CC) with a p-adjusted value > 0.1 
(Benjamini correction). GO terms have been grouped in 5 main groups with a curated analysis. For each GO term the following 
information are reported: the category (BP = Biological Process, MF = Molecular Function, CC = Cellular Component), the number  
of genes, the Fold Enrichment compared to the expected number of genes in the human genome, the Benjamini adjusted p-value 
resulting from the modified Fisher Exact test (EASE score).            
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4.2.4.1 Pathways of the innate immune response 
 
At day 7, it was observed the downregulation of pathways involved in the 
recognition of pathogens such as Toll-like receptor and C-type lectin receptor 
signaling pathways [Figure 16]. Downregulation involves receptors TLR1, 
TLR2, TLR4, TLR5, TLR8 as well as the protein kinase IRAK4 necessary in 
the downstream signaling leading to the transcriptional activation of 
inflammatory genes. On the contrary upregulation of TLR7 is observed. The 
c-type lectin receptors CLEC4D, CLEC6A (alias Dectin2), CLEC4E (alias 
Mincle) are downregulated as well as the adaptor molecule FCER1G (Fc 
Receptor Gamma-Chain) and the tyrosine kinase SYK acting in the 
downstream signaling pathways that modulate cytokine expression. 
Pathways involving recognition of antigens bound to immunoglobulins IgE 
and IgG are also modified. 
 
  
Figure 16 Bar plot showing the number of upregulated genes (red) and 
downregulated genes (green) at day 7 compared to day 1. GO terms in the cluster 
of innate immune response are reported. 
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4.2.4.2 Pathways of immune response and inflammation 
 
A regulation of the inflammatory pathway is observed at day 7: receptors of 
the powerful proinflammatory cytokines IL1 and IL18  (respectively IL1R2, 
IL1RAP and IL18R1 and IL18RAP), are downregulated. The alarmins 
S100A8, S100A9, S100A12 which have a proinflammatory activity are 
downregulated as well as the genes of the proteasome and genes of NFKB 
signaling pathway [Figure 17].  
Prostaglandin-endoperoxide synthase (PTGS2), the key enzyme in 
prostaglandin biosynthesis is upregulated as well as ALOX15, a 
lipoxygenase converting arachidonic acid and generating a spectrum of 
bioactive lipid mediators. On the contrary PTGER2 and LTB4R that are 
respectively receptors for prostaglandins and leukotrienes, inflammatory 
lipids derived from arachidonic acid, are downregulated. Upregulation is 
observed also for CHI3L1, a carbohydrate-binding lectin, playing a role in the 
process of inflammation and tissue remodeling and OLR1, a receptor that 
mediates the recognition, internalization and degradation of oxidatively 
modified low density lipoprotein (oxLDL).  
Molecules with endopeptidase activity potentially involved in the 
inflammatory and remodeling processes of the extracellular matrix are also 
dysregulated: the metalloproteases ADAMTS3, MMP8 and MMP9 are 
downregulated at day 7 whereas HtrA serine peptidase (HTRA3), Neutrophil 
Elastase (ELANE) and the metalloendopeptidase Neprilysin (MME) are 
upregulated at the same timepoint. Genes involved in cell adhesion and 
leukocyte migration are also regulated: at day 7 the expression of CD177, 
CD44, and CEACAM1 is decreased whereas the expression of CEACAM6 
and CEACAM8 is increased.  
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Figure 17 Bar plot showing the number of upregulated genes (red) and 
downregulated genes (green) at day 7 compared to day 1. GO terms in the cluster 
of immune response and inflammation are reported. 
 
4.2.4.3 Pathways of adaptive immune response: T and B lymphocytes 
 
At steady state (Day 7), genes involved in T cell activity are upregulated: CD4 
receptor (T helper) that  interacts with the major histocompatibility complex 
class II antigens, CD8A and CD8B receptors in cytotoxic T cells recognizing 
antigens displayed by antigen presenting cell (APC) in the context of class I 
MHC molecules. Genes involved in T cell costimulation also increase their 
expression: CD28 and CD26 (alias DPP4) expressed on T lymphocytes and 
CD86 expressed on APCs. Upregulation is reported also for genes with 
adaptor function in the T cell receptor signaling (TRAT1 and LAX1) and for 
kinases involved in the initial step of TCR-mediated signal transduction 
(ZAP70 and LCK).  
Genes involved in B cell activation encoding the heavy chain (IGHG1, 
IGHV3-23, IGHG3, IGHA2, IGHA1, IGHG4, IGHG2), and the light chain of 
immunoglobulins (IGKC, IGLC3, IGLC2) are upregulated at day 7 [Figure 
18]. 
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Figure 18 Bar plot showing the number of upregulated genes (red) and 
downregulated genes (green) at day 7 compared to day 1. GO terms in the cluster 
of adaptive immune response are reported. 
 
4.2.4.4 Vesicles 
 
A regulation of genes involved in vesicle transport between endoplasmic 
reticulum and Golgi apparatus was observed, particularly related to COPII 
coated vesicles. Enrichment in genes related to extracellular exosomes and 
blood microparticles is also found [Figure 19]. These genes were 
downregulated at day 7, suggesting their role in the acute phase T1. 
 
 
Figure 19 Bar plot showing the number of upregulated genes (red) and 
downregulated genes (green) at day 7 compared to day 1. GO terms in the cluster 
of vesicles processes are reported. 
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4.2.4.5 Protein synthesis 
 
Increased expression was observed for genes related to protein synthesis. 
Genes encoding constituents of small and large ribosomal subunits and 
involved in rRNA processing are upregulated at day 7 [Figure 20]. Differential 
expression was observed for genes involved in translational initiation (EIF3L, 
EIF4E3). 
 
 
 
Figure 20 Bar plot showing the number of upregulated genes (red) and 
downregulated genes (green) at day 7 compared to day 1. GO terms in the cluster 
of protein synthesis are reported.  
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4.2.5 Analysis of top differentially expressed genes 
 
In order to identify the most involved molecular functions in the transition from 
the acute phase of shock to the steady state, we selected the top upregulated 
or downregulated genes applying  a threshold on the log2FoldChange value.  
Up or down regulation always refer to T3 compared to T1. A total of 149 
genes with a log2FoldChange > 2 or < -2 were identified and their molecular 
functions were analyzed using a curated approach. Sixty three genes were 
associated to common biological processes or molecular functions [Table 9]. 
With this approach we observed a strong upregulation of 27 genes encoding 
the heavy and light chains of immunoglobulins. Among the genes related to 
immune functions and inflammation, downregulation was observed for 
receptors of the IL-1 family, the alarmin S100A12 and for CD163, a receptor 
involved in the acute phase of inflammation, exclusively expressed in 
monocytes and macrophages  In the same biological group on the contrary, 
galectin 2 and chitinase 3 like 1, involved in inflammation and tissue 
remodeling were upregulated. Molecules of the class of lipid mediators, that 
are known as key players in the resolution of inflammation and in the return 
to homeostasis, were either up or down regulated in the steady state. The 
lipid receptors FFAR3, S1PR1 and FABP2 and two  genes involved in the 
metabolism of prostaglandins and leukotrienes (HPGD and ALOX15B) were 
downregulated. OLR1, the receptor of oxidized LDL, ALOX15, the 
arachidonate 15-lipoxygenase, PTGDR2, a prostaglandin receptor, and 
SCARF1, involved in the clearance of apoptotic cells were upregulated. Four 
genes involved in carbohydrate metabolism showed lower expression at 
steady state condition. Upregulation was observed for CAMP, DEFA3 and 
DEFA4  encoding peptides with antimicrobial functions and myeloperoxidase 
producing hypohalous acids with microbicidal activity. 
Genes encoding proteases involved in antimicrobial functions, inflammation 
and tissue remodeling were also markedly downregulated and upregulated. 
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Table 9 Functional analysis of top differentially expressed genes. Sixty three  genes 
showing high fold-induction were clustered in 6 biological groups based on their 
function. 
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4.2.6 Analysis of long non coding RNAs 
 
The expression of long non coding RNAs (lncRNAs) was analyzed in order 
to identify transcripts associated to septic shock condition, potentially useful 
as biomarkers. A total of 30 lncRNAs differentially expressed between the 
acute phase of septic shock and the steady state, were identified after 
applying a fold change threshold (log2FC >1 or < -1) [Table 11]. The lncRNA 
with the highest level of significance is LINC01127. It is located on chr 2 
upstream the IL1R2 gene and other interleukin receptors of the IL1 family of 
cytokines (IL1R1, IL1RL2, IL18R1, IL1RL1, IL18RAP). Four of the cited 
interleukin receptors are downregulated in our experiment showing 
coexpression with LINC01127 [Table 10]. In this region is also located 
MIR4772, a microRNA previously associated to sepsis. Downregulation was 
also observed for MIAT, a lncRNA previously associated to myocardial 
infarction and cardiac hypertrophy.  
 
 
 
Table 10 LINC01127 is coordinately downregulated with downstream located genes 
encoding interleukin receptors. Log2FC is log2FoldChange of Day 7 expression 
compared to day 1. FDR stands for False Discovery Rate. 
 
 
 
53 
 
 
Table 11 List of thirty differentially expressed long non coding RNAs between the 
acute phase and steady state of septic shock. Log2FC is log2FoldChange of Day 7 
expression compared to day 1. FDR stands for False Discovery Rate. 
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4.3 microRNA analysis 
 
The miRNA dataset includes 75 biological samples collected from 32 shock 
patients. Gene expression profiling is available for 32 patients at day 1 (T1), 
for 25 patients at day 3 (T2) and for 18 patients at day 7 (T3). On average, 7 
M reads per sample were produced, that represent an adequate number of 
reads to capture a meaningful fraction of miRNA present in the samples. 
Principal Component Analysis (PCA) was used to analyze normalized gene 
counts [Figure 21].  
 
 
Figure 21 PCA of 14 SS patients at multiple timepoints based on the top 50 variable 
miRNAs. PC1 and PC2 of each biological sample are shown in a two-dimensional 
plot. Different colors are used to identify samples at different timepoints according to 
the legend. 
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Contrary to what we observed in the PCA plot of gene expression data 
[Figure 10], in the PCA plot of microRNA data we couldn’t observe a 
clusterization of biological samples based on timepoints. Instead, microRNA 
expression shows a high inter-patient variability. Given this high variability, 
we  decided to analyze a subgroup of patients, as homogeneous as possible. 
Patients were selected based on the same criteria used for RNASeq 
analysis: we focused on the condition of acute phase of shock (Day 1) and 
the condition of steady state (Day 7); 4 SS patients (E17, E32, G28 and G08) 
were excluded from the dataset because in the clustering analysis of 
RNASeq their gene expression profile was different compared to most of the 
other samples in the dataset. Based on this, 14 patients were selected to 
investigate microRNA expression. Eight differentially expressed microRNAs 
were identified after applying filters based on average number of sequences 
covering each miRNA, p value of significance of the difference, logFC of the 
difference (basemean > 10, significance level of 0.05, logFC > 0.5) (Table 
12). 
 
microRNA_ID log2FoldChange FDR 
hsa-miR-125a-5p 1.57 5.60E-10 
hsa-miR-150-5p 1.18 4.47E-06 
hsa-miR-99b-5p 0.93 0.003 
hsa-miR-193a-3p -1.33 0.012 
hsa-miR-199b-5p -0.77 0.015 
hsa-miR-26b-3p -0.78 0.015 
hsa-miR-27a-3p -0.63 0.017 
hsa-miR-96-5p -0.66 0.018 
   
Table 12 List of differentially expressed microRNAs between the acute phase and 
steady state of septic shock. Log2FC is log2FoldChange of Day 7 expression 
compared to day 1. FDR stands for False Discovery Rate. 
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The expression of the top 2 upregulated and of the top downregulated 
miRNA are shown with expression boxplots [Figure 22, Figure 23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Expression boxplots of microRNAs 125a-5p and 150-5p showing 
upregulation in the steady state of septic shock (T3) compared to the acute phase of 
shock (T1). 
Figure 23 Expression boxplot of microRNA 193a-3p showing its downregulation in the 
steady state of septic shock (T3) compared to the acute phase of shock (T1). 
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4.3.1 “In silico” target prediction 
 
Three microRNAs showing high expression fold change (log2FoldChange >1 
or < -1)  were selected in order to identify their putative targets: the top2 
upregulated hsa-miR-125a-5p and hsa-miR-150-5p, and the downregulated 
hsa-miR-193a-3p. At this purpose we used TargetScan 7.1 database and 
identified 946 target genes for miR-125a-5p, 439 targets for miR-150-5p and 
340 targets for miR-193a-3p.  
 
 
4.3.1.1 Targets of upregulated miRNAs miR-125a-5p and miR-150-5p  
 
Since miR-125a-5p and miR-150-5p are both upregulated, the lists of their 
targets were merged, generating a list of 1329 target genes. As expected, 
the number of targets of the two miRNA is very high and unlikely to be used 
for any further investigation. Therefore, being the two miRNA upregulated, 
we searched, in the list of genes downregulated in the RNAseq experiment, 
for those genes that are targets of miR-125 and miR-150. In this way we 
could restrict the list to 193 genes [Figure 24] showing downregulation in the 
RNASeq experiment. This shortened list was used for a more in depth 
downstream analysis. An overrepresentation analysis of these 193 genes 
identified a significant GO enrichment for the pathway “hsa04010:MAPK 
signaling” with a Benjamini adjusted p-value of 0.015. Eleven genes in MAP 
Kinase pathway are downregulated in the RNAseq experiment and are 
targets of miR125a-5p and/or miR150-5p (DUSP3, RPS6KA1, TAOK1, 
MAPK14, TGFBR1, MAP3K1, MAPK10, TRAF6, SRF, MAP2K6, RASA2). 
MAPK10 and MAPK14 are also known with the name of JNK3 and p38 that 
are important regulatory molecules in the MAPK pathway.   
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Figure 24 Venn diagram showing the filtering procedure applied to the list of target 
genes obtained from TargetScan database. The list of 1329 targets was intersected 
with the list of 2437 downregulated genes in the RNASeq experiment (FDR < 0.01) 
considering the same comparison (Day1 – Day7). A total of 193 genes defined as 
targets of miR125a-5p or miR150-5p were downregulated in our dataset. 
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4.3.1.2 Targets of the downregulated miRNA miR-193a-3p 
 
We identified 340 targets for miR-193a-3p, that is downregulated at T3. With 
the aim to circumscribe the list of target genes, we concentrated on targets 
that were upregulated  genes in RNAseq experiment. In this way we reduced 
the number to 38 targets [Figure 25]. 
 
 
Figure 25 Venn diagram showing the filtering procedure applied to the list of target 
genes obtained from TargetScan database. The list of 340 targets was intersected 
with the list of 2403 upregulated genes in the RNASeq experiment (FDR < 0.01) 
considering the same comparison (Day1 – Day7). A total of 38 genes defined as 
targets of miR-193a-3p were upregulated in our dataset. 
 
Gene Ontology overrepresentation analysis didn’t identify any significative 
GO enrichment in the list of 38 upregulated targets. Nevertheless we were 
able to observe the presence of 3 genes involved in the response to hypoxia: 
ETS1, PLAU and TGFBR3.   
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5 DISCUSSION 
 
We analyzed the transcriptomic profile of septic shock patients at three 
critical points of the clinical course, to investigate the molecular mechanisms 
involved, in relation to the clinical condition. The experimental design of this 
study includes a follow up of the patients during the ICU stay, from admission 
up to 7 days of the ICU stay [59]. This represents an important asset that can 
help to pinpoint genes and molecular pathways that are at work during the 
period of observation. As far as we know this is the first transcriptomic study 
in septic shock patients with a follow up of 7 days. In fact, most papers 
published so far that have profiled the transcriptome in septic shock have 
evaluated patients at the time of their admission to the ICU[60]–[62] or in the 
early phase after ICU admission [63]. We performed the RNAseq 
experiments in peripheral blood cells, that are the first line of immune 
defense system and continuously interact with the other tissues and organs 
of the body. In circulating blood cells the expression of a large proportion of 
the genes encoded in human genome can be detected. It has been 
demonstrated that  these cells can be used as surrogate tissue since 
changes of their gene expression can provide useful information on health or 
disease condition of any tissue [64].  
The first analysis performed on the whole dataset of RNAseq data was an 
exploratory data analysis. We used at this purpose a Principal Component 
Analysis to reduce the complexity of the dataset and to describe the 
variability of gene expression data in the samples processed. From this 
investigation we got three major information: 1) gene expression data clearly 
differentiate the acute phase from the steady state, in line with the different 
clinical conditions observed at the two timepoints. 2) Patients at day 3 are 
much more heterogeneous, similarly to what the clinicians report on the 
patient’s response to treatment that is estimated at day 3. 3) The signature 
61 
 
of 1748 genes identified through the comparison of gene expression across 
timepoints was also used to analyze the inter-patient variability of septic 
shock patients at day 1 (Figure 12). With the unsupervised clustering 
analysis we could appreciate different transcriptional responses in septic 
shock patients homogeneous on a clinical basis. This opens the possibility 
to use the transcriptome analysis to identify, also  in adult septic shock, 
subgroups of patients with different transcriptional profile as previously 
reported by Wong in pediatric septic shock[62]. The inter-individual variability 
observed in the transcriptomic response to septic shock could be possibly 
related to the patient medical history, co-morbidities, genetic factors or 
virulence of the pathogens. At this purpose, a recent study by Davenport et 
al. [60] identified genetic variants influencing the expression level of key 
immune and metabolic genes involved in endotoxin tolerance, T cell 
activation, hypoxic response and switch to glycolysis.   
The innate immune system is the first line of defense against infections and 
in collaboration with the adaptive system plays an important role in 
sepsis[43]. The results of our comparison between the acute phase and the 
steady state are in line with this, and the Gene Ontology overrepresentation 
analysis highlighted the role of the innate and adaptive immune response 
(Table 8). We observed that pathways involved in the recognition of 
pathogens such as Toll-like receptor and C-type lectins are transcriptionally 
downregulated at day 7, in accordance with their function that is mainly 
required in the very initial phase of sepsis when the body needs to counteract  
the infection [65].  Downregulation at steady state was observed also for the 
interleukin receptors IL1R2, IL1RAP, IL18R1, IL18RAP binding the 
proinflammatory cytokines IL-1 and IL-18 and for the alarmins S100A8, 
S100A9, S100A12, that are important mediators of  inflammation[66][67][68]. 
These classes of molecules were described by Tsalik et al. who found higher 
expression in sepsis survivors vs non survivors showing that a proper 
activation of the inflammatory pathway in the initial response to sepsis 
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correlates with positive outcome [61]. Notably serum IL1R2 has been 
recently proposed as a new potential biomarker for the diagnosis of 
sepsis[69]. At day 7 we also observed the upregulation of genes involved in 
the adaptive immune response of T and B lymphocytes. Of note, we 
observed a marked upregulation of 27 immunoglobulin genes encoding the 
heavy chain, the light chain and the variable chain of immunoglobulins 
suggesting that the antibody mediated immunity is highly involved in the 
immunological modifications of septic shock. This is consistent with the 
changes in gene expression in the early phase of septic shock observed by 
Cazalis , who detected a downregulation of functions of the adaptive immune 
response (T cell signaling and antigen presentation genes) together with an 
increased expression of genes of acute inflammation and innate immune 
response[63]. Moreover several studies have reported decreased circulating 
immunoglobulin levels when sepsis develops, in line with the upregulation of 
immunoglobulin genes that we observe at T3 [70]. 
 These observations underline that the initial phase of septic shock (day 1) is 
characterized by an acute inflammatory response, whereas at day 7, the 
pathways of Pattern recognition receptor signaling, alarmins and IL-1 
proinflammatory cytokines are downregulated and the adaptive immune 
functions are increased in accordance to the theory described by Hotchkiss 
[43](Figure 2) and with the microarray study of Wong in a cohort of pediatric 
septic shock.[71]   
Lipids and lipid mediators derived from fatty acids can influence the immune 
system [72][73]. In our dataset, genes encoding enzymes of the lipid pathway 
were differentially expressed at steady state. Among these, the free fatty acid 
receptor FFAR3 and the fatty acid binding protein FABP2, involved in lipid 
metabolism and whole body energy homeostasis[74], [75]. Genes of the 
prostaglandin pathway were also differentially expressed including HPGD, 
the major enzyme involved in the degradation of prostaglandins and the 
prostaglandin receptor PTGDR2 [72][76]. Prostaglandins interact with pro-
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inflammatory cytokines, amplify and modulate inflammation and activate 
resolution [77]. Two genes of the ALOX family, ALOX15B (arachidonate 15-
lipoxygenase, type B) and ALOX15 (arachidonate 15-lipoxygenase) were 
differentially expressed at steady state.  They encode ALOX enzymes that 
are pivotal in the synthesis of resolvins. The expression of HPGD and ALOX 
genes has been described associated to clinical outcome in leukocytes of 
trauma patients [78]. In the same biological pathway of lipid mediators, we 
observed the downregulation of S1PR1, the receptor of the sphingosine-1-
phosphate (SIP), a bioactive lysophospholipid generated from intracellular 
ceramide, a key regulator of microvascular endothelial function [79]. 
Microvascular endothelial dysfunction is a hallmark in sepsis in humans and 
is considered a predictor of outcome in patients with severe sepsis [80]. 
When endothelial function is impaired, the release of the vasodilator nitric 
oxide and prostaglandin is deregulated, vascular reactivity to 
vasoconstrictors is reduced, leukocytes and platelets aggregate [81]. 
In experimental endotoxemia Al Banna et al. [82] have reported the 
contribution of oxidized LDL to leukocyte activation and microvascular 
alterations. At steady state we found the upregulation of OLR1 also called 
LOX1, that is the receptor of oxidized LDL. It is thought that oxidized LDL 
and LOX1 may play a role in the increased inflammation and capillary 
leakage, two factors that induce disturbances in microcirculation. LDL levels 
can be regulated through the action of proprotein convertase subtilisin–kexin 
type 9 (PCSK9) that binds the LDL receptor (LDLR) on hepatocytes and 
promotes its lysosomal degradation[28]. PCSK9 was downregulated at day 
7 suggesting that there is an increased LDLR activity on hepatocytes in line 
with the upregulation of the receptor LOX1. These observations point to a 
modification in the lipid homeostasis and are consistent with the alteration in 
fatty acid metabolism reported in sepsis by Langley in relation to the clinical 
outcome[49].  
From it’s onset, sepsis is characterized by a hypermetabolic condition. Septic 
64 
 
patients have sustained fever, and they have increased need of energy 
supplies [83]. We found a strong downregulation at steady state of genes 
that encode glycolytic enzymes: hexokinase 3 (HK3) that catalyzes the 
phosphorylation of glucose, the first step in glycolysis and in most of glucose 
metabolism pathways; 6-Phosphofructo-2-Kinase (PFKFB2 and PFKFB3) 
that synthetize and degrade fructose-2,6-bisphosphate, a regulatory 
molecule that strongly activates glycolysis; IDNK a gene with gluconokinase 
activity. A higher expression of genes of the glycolytic pathway during the 
acute phase of shock could be explained by the increased anaerobic 
metabolism that is activated when hypoxia occurs in septic shock and causes 
hyperlactatemia, a common finding associated to sepsis[83], that we also 
observed in our cohort of patients. Hyperlactatemia is a marker of the 
metabolic stress response. Hyperlactatemia  could also indicate an 
accelerated aerobic glycolysis that can occur in non-hypoxic 
circumstances[6]. This is an alternative explanation for sepsis-associated 
hyperlactatemia and the downregulation of genes of the glycolytic pathway 
at steady state that we observed could reflect the change in metabolic state 
that occurred in the acute shock condition at T1.  
At day 7 we observed the increased expression of genes involved in defense 
mechanisms to pathogens, including the  Myeloperoxidase enzyme, the 
serine proteases Elastase, Cathepsin G and Proteinase 3, the antimicrobial 
peptides Defensin Alpha 3, Defensin Alpha 4 and the Cathelicidin 
Antimicrobial Peptide. These molecules are expressed in neutrophil granules  
and partecipate in bacterial killing through several mechanisms: production 
of hypohalous acids (myeloperoxidase),  degradation of engulfed pathogens 
(serine proteases) and permeabilization of bacterial plasma membrane 
(antimicrobial peptides) [84]. We hypothesize that the increased expression 
of antimicrobial systems in the steady state of shock could be useful to 
control the primary infection and prevent secondary infections, which in a 
recent study were estimate to affect 13% of sepsis patients [85]. The 
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Cathelicidin Antimicrobial Peptide has been also associated to suppression 
of the pyroptosis of macrophages and inflammatory cytokine production in a 
murine model of sepsis [86] suggesting that it could be implicated in the 
decrease of the inflammatory state observed in the first week after the ICU 
admission. Beyond Neutrophil serine proteases, we observed the modulation 
of several genes with protease activity. In our patients at T3 the 
metalloproteases MMP8 and MMP9, decrease their level of expression. 
Accordingly, in the FINNSEPSIS study cohort both MMP8  and MMP9 were 
upregulated in early phase of severe sepsis compared to healthy controls 
and high serum level of MMP8 have been associated to fatal outcome [87]. 
Metalloproteases can degrade extracellular matrix proteins, modulate the 
inflammatory responses and tissue repair [88] and can modify blood pressure 
by several mechanisms [89]. ADAMTS3 metallopeptidase involved in the 
cleavage of propeptides of type II collagen, showed the same downregulated 
expression trend suggesting that ADAMTS3 could participate in the 
extracellular matrix remodeling in septic shock. Upregulation was observed 
for MME, the metalloendopeptidase neprilysin  involved in the inactivation of 
several peptide hormons like angiotensins and the atrial natriuretic factor, 
and previously associated to outcome in acute heart failure[90].  PLAU, the 
plasminogen activator urokinase involved in fibrin degradation, 
coagulation[91], cardiac fibrosis[92] and heart failure [93] was upregulated 
as well. These findings indicates a potential role of proteases in the 
regulation of factors affecting the cardiovascular system in septic shock and 
are in line with the work of Sharony et al.[94], which highlights the role of 
proteases in the cardiovascular system. These results support the 
hypothesis that proteases could be an important factor in the development 
of circulatory shock and subsequent multiorgan failure as suggested by 
previous studies on the role of intestinal proteases in shock [95]. 
At steady state, we observed an increased expression of genes involved in 
protein synthesis such as structural constituent of ribosomes and genes 
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involved in control of translation. A reduction of protein synthesis has been 
previously observed by Vary and Kimball[96] in muscles of septic rats. Our 
transcriptomic data suggest that a similar reduction in protein synthesis 
occurs also in human blood cells, in the acute phase of septic shock. This 
could be a conservative metabolic strategy, promoting cell survival by 
inhibiting biological processes not essential during the critical condition of 
day 1. A decreased expression of genes involved in the transport of vesicles 
from the endoplasmic reticulum to Golgi was observed at day 7, particularly 
regarding vesicles coated with COPII proteins. This observation, together 
with the high number of identified DEGs related to extracellular exosomes, 
suggest there could be an increased release of vesicles in the extracellular 
space in the acute phase of septic shock. This is consistent with a recent 
finding by Lehner et al.[97] who detected a higher number of circulating 
microvesicles released by platelets and leukocytes in septic shock patients 
compared to controls.  
Previous transcriptomic analysis in sepsis and septic shock were mainly 
focused on expression of coding genes or microRNAs [60], [61], [63], [98]. 
Our analysis explored not only coding RNAs and microRNAs, but also long 
noncoding RNAs. Long noncoding RNAs (lncRNAs) have gained attention 
as  potential new biological regulators and have been implicated in a range 
of developmental processes and diseases [99]. Long ncRNAs can play a fine 
regulatory role of gene expression through mechanisms of mediated RNA 
decay or acting as decoys for miRNAs[100]. Our analysis identified 30 
lncRNAs differentially expressed in septic shock comparing T1 to T3. Among 
these, LINC01127 was downregulated at T3 in the RNASeq analysis. The 
function of LINC01127 is unknown, but its genomic position, upstream the 
genes coding the receptors of IL-1 and IL-18, suggests that it could play a 
role in the context of acute inflammation. The long ncRNA MIAT, 
downregulated at steady state, is reported as a transcript associated to 
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myocardial infarction and plays a role in cardiac hypertrophy by sponging 
mir-150[101].  
Comparing day 1 to day 7, we observed the differential expression of some 
microRNAs. miR-125a-5p and miR-150-5p, that are upregulated at day 7, 
were previously reported as markers of sepsis, when septic patients were 
compared with healthy controls[98]. In line with the case control study of 
septic patients vs healthy subjects of Ma et al., we observed a low level of  
miR-125a-5p and miR-150-5p during the acute phase of septic shock and a 
higher level at steady state, suggesting that their regulatory activity is 
reduced during the acute phase of shock and then recovered at steady state. 
The “in silico” search for their target genes indicated that miR-125a-5p and 
miR-150-5p could have a role in the regulation of the MAPK pathway. In 
detail, their upregulation at day 7 could result in an inhibitory action of the 
MAPK pathway. On the contrary, in the acute phase, downregulation of miR-
125a-5p and miR150-5p could result in the activation of the MAPK pathway 
that is involved in the signaling cascade of toll-like receptor[102] and of the 
inflammatory pathways[103], that are important pathways in septic shock. 
miR-150 was previously linked to cardiac hypertrophy and fibrosis and its 
availability is under the control of the long ncRNA MIAT, which was also 
identified in our analysis [101]. We speculate that these two molecules could 
be involved in the cardiovascular complications of sepsis that can lead the 
patient to acute heart failure. Downregulation at steady state was also 
observed for miR-193a-3p. Among its predicted targets PLAU, the 
plasminogen activator urokinase, is an important factor controlling blood 
coagulation with a beneficial effect against disseminated intravascular 
coagulation that is often associated to septic shock[104].  
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6 CONCLUSION 
 
In this work our aim was to illustrate the complex modifications of blood cell 
transcriptomic profile in septic shock in a well characterized cohort at three 
timepoints. We identified two major transcriptomic profiles, corresponding to 
the clinical conditions of acute phase (day 1) and steady state of shock (day 
7) and we showed that different groups of patients can be identified based 
on their –omic profile. The expression profile of the two conditions was 
different in multiple pathways, including the pathways of innate and adaptive 
immune response, metabolic pathways of lipids and glycolysis, antimicrobial 
systems, proteases and processes involving extracellular vesicles. These 
findings supported the results of previous works in sepsis and septic shock 
with the added value to analyze the patients during a period of 7 days. We 
proposed that miR-125a-5p and miR-150-5p could have a regulatory role on 
the MAPK pathway in septic shock and we newly identified 30 long ncRNAs 
differentially expressed between the acute phase and steady state. Future 
investigations will concern the analysis in the same cohort of the expression 
profile in relation to the clinical outcomes and the response to therapy.  
 
 
 
 
 
 
 
 
  
 
69 
 
7 BIBLIOGRAPHY  
 
[1] M. Singer, C. S. Deutschman, C. W. Seymour, M. Shankar-Hari, D. 
Annane, M. Bauer, R. Bellomo, G. R. Bernard, J.-D. Chiche, C. M. 
Coopersmith, R. S. Hotchkiss, M. M. Levy, J. C. Marshall, G. S. Martin, 
S. M. Opal, G. D. Rubenfeld, T. van der Poll, J. Vincent, and D. C. 
Angus, “The Third International Consensus Definitions for Sepsis and 
Septic Shock (Sepsis-3).,” Jama, vol. 315, no. 8, pp. 801–10, 2016. 
[2] G. S. Martin, D. M. Mannino, and M. Moss, “The effect of age on the 
development and outcome of adult sepsis.,” Crit. Care Med., vol. 34, 
no. 1, pp. 15–21, 2006. 
[3] G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, “The 
epidemiology of sepsis in the United States from 1979 through 2000.,” 
N. Engl. J. Med., vol. 348, no. 16, pp. 1546–54, 2003. 
[4] A. M. Esper, M. Moss, C. A. Lewis, R. Nisbet, D. M. Mannino, and G. 
S. Martin, “The role of infection and comorbidity: Factors that influence 
disparities in sepsis.,” Crit. Care Med., vol. 34, no. 10, pp. 2576–82, 
2006. 
[5] P. A. Ward, “New approaches to the study of sepsis,” EMBO Mol. 
Med., vol. 4, no. 12, pp. 1234–1243, 2012. 
[6] M. Garcia-alvarez, P. Marik, and R. Bellomo, “Sepsis-associated 
hyperlactatemia,” pp. 1–11, 2014. 
[7] J. Cohen, J. L. Vincent, N. K. J. Adhikari, F. R. Machado, D. C. Angus, 
T. Calandra, K. Jaton, S. Giulieri, J. Delaloye, S. Opal, K. Tracey, T. 
van der Poll, and E. Pelfrene, “Sepsis: A roadmap for future research,” 
Lancet Infect. Dis., vol. 15, no. 5, pp. 581–614, 2015. 
[8] D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, 
and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: 
analysis of incidence, outcome, and associated costs of care.,” Crit. 
70 
 
Care Med., vol. 29, no. 7, pp. 1303–1310, 2001. 
[9] G. Pawelec, R. Solana, E. Remarque, and E. Mariani, “Impact of aging 
on innate immunity.,” J Leukoc Biol, vol. 64, no. 6, pp. 703–712, 1998. 
[10] H. Bruunsgaard, P. Skinhoj, J. Qvist, and B. K. Pedersen, “Elderly 
humans show prolonged in vivio inflammatory activity during 
pneumococcal infections,” J. Infect. Dis., vol. 180, pp. 551–554, 1999. 
[11] J.-L. Vincent, Y. Sakr, C. L. Sprung, V. M. Ranieri, K. Reinhart, H. 
Gerlach, R. Moreno, J. Carlet, J.-R. Le Gall, and D. Payen, “Sepsis in 
European intensive care units: results of the SOAP study.,” Crit. Care 
Med., vol. 34, no. 2, pp. 344–353, 2006. 
[12] T. J. Iwashyna, E. W. Ely, D. M. Smith, and K. M. Langa, “Long-term 
Cognitive Impairment and Functional Disability Among Survivors of 
Severe Sepsis,” vol. 304, no. 16, pp. 1787–1794, 2016. 
[13] R. S. Hotchkiss, L. L. Moldawer, S. M. Opal, K. Reinhart, I. R. Turnbull, 
and J.-L. Vincent, “Sepsis and septic shock,” Nat. Rev. Dis. Prim., vol. 
2, no. August, p. 16045, 2016. 
[14] A. Kumar, P. Ellis, and Y. Arabi, “Initiation of Inappropriate 
Antimicrobial Therapy Results in a Fivefold Reduction of Survival in 
Human Septic Shock,” Chest, vol. 136, no. 5, pp. 1237–1248, 2009. 
[15] J.-L. Vincent, A. de Mendonca, F. Cantraine, R. Moreno, J. Takala, P. 
M. Suter, C. L. Sprung, F. Colardyn, and S. Blecher, “Use of the SOFA 
score to assess the incidence of organ dysfunction/failure in intensive 
care units,” Crit. Care Med., vol. 26, no. 11, pp. 1793–1800, 1998. 
[16] K. J. Ishii, S. Koyama, A. Nakagawa, C. Coban, and S. Akira, “Host 
Innate Immune Receptors and Beyond: Making Sense of Microbial 
Infections,” Cell Host Microbe, vol. 3, no. 6, pp. 352–363, 2008. 
[17] P. Matzinger, “The danger model: a renewed sense of self,” Science 
(80-. )., vol. 296, pp. 301–305, 2002. 
[18] E. Meylan, J. Tschopp, and M. Karin, “Intracellular pattern recognition 
receptors in the host response,” Nature, vol. 442, no. July, pp. 39–44, 
71 
 
2006. 
[19] T. B. H. Geijtenbeek and S. I. Gringhuis, “Signalling through C-type 
lectin receptors: shaping immune responses.,” Nat. Rev. Immunol., 
vol. 9, no. 7, pp. 465–79, 2009. 
[20] N. M. Foley, J. Wang, H. Redmond, and J. Wang, “Current knowledge 
and future directions of TLR and NOD signaling in sepsis,” Mil. Med. 
Res., vol. 2, no. 1, p. 1, 2015. 
[21] S. K. Biswas and E. Lopez-Collazo, “Endotoxin tolerance: new 
mechanisms, molecules and clinical significance,” Trends in 
Immunology, vol. 30, no. 10. pp. 475–487, 2009. 
[22] M. Lamkanfi  Sarkar, A., Vande Walle, L., Vitari, A. C., Amer, A. O., 
Wewers, M D., Tracey, K. J., Kanneganti, T.-D., Dixit, V. M., 
“Inflammasome-dependent release of the alarmin HMGB1 in 
endotoxemia,” J. Immunol., vol. 185, no. 7, pp. 4385–4392, 2010. 
[23] P. A. Ward and H. Gao, “Sepsis, complement and the dysregulated 
inflammatory response,” J. Cell. Mol. Med., vol. 13, no. 10, pp. 4154–
4160, 2009. 
[24] J. E. Gotts and M. A. Matthay, “Sepsis: pathophysiology and clinical 
management,” Bmj, vol. 353, p. i1585, 2016. 
[25] D. C. (Pitt) Angus and T. van der Poll, “Severe sepsis and septic 
shock.,” N. Engl. J. Med., vol. 369, no. 9, pp. 840–51, 2013. 
[26] Y. Kakihana, T. Ito, M. Nakahara, K. Yamaguchi, and T. Yasuda, 
“Sepsis-induced myocardial dysfunction; pathophysiology and 
management,” J. Intensive Care, vol. 4, p. 22, 2016. 
[27] G. W. Schmid-Schönbein and M. Chang, “The autodigestion 
hypothesis for shock and multi-organ failure,” in Annals of Biomedical 
Engineering, 2014, vol. 42, no. 2, pp. 405–414. 
[28] K. R. Walley, G. A. Francis, S. M. Opal, E. A. Stein, J. A. Russell, and 
J. H. Boyd, “The central role of proprotein convertase subtilisin/kexin 
type 9 in septic pathogen lipid transport and clearance,” Am. J. Respir. 
72 
 
Crit. Care Med., vol. 192, no. 11, pp. 1275–1286, 2015. 
[29] J. R. Prowle and R. Bellomo, “Sepsis-Associated Acute Kidney Injury: 
Macrohemodynamic and Microhemodynamic Alterations in the Renal 
Circulation,” Semin. Nephrol., vol. 35, no. 1, pp. 64–74, 2015. 
[30] R. Alobaidi, R. K. Basu, S. L. Goldstein, and S. M. Bagshaw, “Sepsis-
Associated Acute Kidney Injury,” Seminars in Nephrology, vol. 35, no. 
1. pp. 2–11, 2015. 
[31] M. Ziaja, “Septic encephalopathy topical collection on infection,” Curr. 
Neurol. Neurosci. Rep., vol. 13, no. 10, 2013. 
[32] P. Schramm, K. U. Klein, L. Falkenberg, M. Berres, D. Closhen, K. J. 
Werhahn, M. David, C. Werner, and K. Engelhard, “Impaired 
cerebrovascular autoregulation in patients with severe sepsis and 
sepsis-associated delirium.,” Crit. Care, vol. 16, no. 5, p. R181, 2012. 
[33] A. M. Drewry, N. Samra, L. P. Skrupky, B. M. Fuller, S. M. Compton, 
and R. S. Hotchkiss, “Persistent lymphopenia after diagnosis of sepsis 
predicts mortality.,” Shock, vol. 42, no. 5, pp. 383–91, 2014. 
[34] R. Taneja, A. P. Sharma, M. B. Hallett, G. P. Findlay, and M. R. Morris, 
“Immature Circulating Neutrophils in Sepsis Have Impaired 
Phagocytosis and Calcium Signaling,” Shock, vol. 30, no. 6, pp. 618–
622, 2008. 
[35] J. S. Boomer, K. To, K. C. Chang, O. Takasu, D. F. Osborne, A. H. 
Walton, T. L. Bricker, S. D. Jarman, D. Kreisel, A. S. Krupnick, A. 
Srivastava, P. E. Swanson, J. M. Green, and R. S. Hotchkiss, 
“Immunosuppression in patients who die of sepsis and multiple organ 
failure.,” JAMA, vol. 306, no. 23, pp. 2594–605, 2011. 
[36] M. Hynninen, V. Pettilä, O. Takkunen, R. Orko, S.-E. Jansson, P. 
Kuusela, R. Renkonen, and M. Valtonen, “Predictive value of 
monocyte histocompatibility leukocyte antigen-DR expression and 
plasma interleukin-4 and -10 levels in critically ill patients with sepsis.,” 
Shock, vol. 20, no. 1, pp. 1–4, 2003. 
73 
 
[37] R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, K. C. Chang, J. P. 
Cobb, T. G. Buchman, S. J. Korsmeyer, and I. E. Karl, “Prevention of 
lymphocyte cell death in sepsis improves survival in mice.,” Proc. Natl. 
Acad. Sci. U. S. A., vol. 96, no. 25, pp. 14541–6, 1999. 
[38] R. S. Hotchkiss, R. E. Schmieg, P. E. Swanson, B. D. Freeman, K. W. 
Tinsley, J. P. Cobb, I. E. Karl, T. G. Buchman, and R. E. S. Jr, “Rapid 
onset of intestinal epithelial and lymphocyte apoptotic cell death in 
patients with trauma and shock.,” Crit. Care Med., vol. 28, no. 9, pp. 
3207–17, 2000. 
[39] R. E. Voll, M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden, and I. 
Girkontaite, “Immunosuppressive effects of apoptotic cells.,” Nature, 
vol. 390, no. 6658, pp. 350–1, 1997. 
[40] D. R. Green and H. M. Beere, “Apoptosis. Gone but not forgotten.,” 
Nature, vol. 405, no. 6782, pp. 28–29, 2000. 
[41] G. P. Otto, M. Sossdorf, R. A. Claus, J. Rödel, K. Menge, K. Reinhart, 
M. Bauer, and N. C. Riedemann, “The late phase of sepsis is 
characterized by an increased microbiological burden and death 
rate.,” Crit. Care, vol. 15, no. 4, p. R183, 2011. 
[42] A. H. Walton, J. T. Muenzer, D. Rasche, J. S. Boomer, B. Sato, B. H. 
Brownstein, A. Pachot, T. L. Brooks, E. Deych, W. D. Shannon, J. M. 
Green, G. A. Storch, and R. S. Hotchkiss, “Reactivation of multiple 
viruses in patients with sepsis,” PLoS One, vol. 9, no. 2, p. e98819, 
2014. 
[43] R. S. Hotchkiss, G. Monneret, and D. Payen, “Sepsis-induced 
immunosuppression: from cellular dysfunctions to immunotherapy.,” 
Nat. Rev. Immunol., vol. 13, no. 12, pp. 862–874, 2013. 
[44] D. Brealey, M. Brand, I. Hargreaves, S. Heales, J. Land, R. Smolenski, 
N. A. Davies, C. E. Cooper, and M. Singer, “Association between 
mitochondrial dysfunction and severity and outcome of septic shock,” 
Lancet, vol. 360, no. 9328, pp. 219–223, 2002. 
74 
 
[45] C. S. Deutschman and K. J. Tracey, “Sepsis: Current dogma and new 
perspectives,” Immunity, vol. 40, no. 4, pp. 463–475, 2014. 
[46] Z. a Puthucheary, J. Rawal, M. McPhail, B. Connolly, G. Ratnayake, 
P. Chan, N. S. Hopkinson, R. Phadke, R. Padhke, T. Dew, P. S. Sidhu, 
C. Velloso, J. Seymour, C. C. Agley, A. Selby, M. Limb, L. M. Edwards, 
K. Smith, A. Rowlerson, M. J. Rennie, J. Moxham, S. D. R. Harridge, 
N. Hart, and H. E. Montgomery, “Acute skeletal muscle wasting in 
critical illness.,” JAMA, vol. 310, no. 15, pp. 1591–600, 2013. 
[47] W. H. Hartl and K. W. Jauch, “Metabolic self-destruction in critically ill 
patients: Origins, mechanisms and therapeutic principles,” Nutrition, 
vol. 30, no. 3, pp. 261–267, 2014. 
[48] M. Ferrario, A. Cambiaghi, L. Brunelli, S. Giordano, P. Caironi, L. 
Guatteri, F. Raimondi, L. Gattinoni, R. Latini, S. Masson, G. Ristagno, 
and R. Pastorelli, “Mortality prediction in patients with severe septic 
shock : a pilot study using a target metabolomics approach,” Nat. Publ. 
Gr., no. August 2015, pp. 1–11, 2016. 
[49] R. J. Langley, E. L. Tsalik, J. C. van Velkinburgh, S. W. Glickman, B. 
J. Rice, C. Wang, B. Chen, L. Carin, A. Suarez, R. P. Mohney, D. H. 
Freeman, M. Wang, J. You, J. Wulff, J. W. Thompson, M. A. Moseley, 
S. Reisinger, B. T. Edmonds, B. Grinnell, D. R. Nelson, D. L. 
Dinwiddie, N. a Miller, C. J. Saunders, S. S. Soden, A. J. Rogers, L. 
Gazourian, L. E. Fredenburgh, A. F. Massaro, R. M. Baron, A. M. K. 
Choi, G. R. Corey, G. S. Ginsburg, C. B. Cairns, R. M. Otero, V. G. 
Fowler, E. P. Rivers, C. W. Woods, and S. F. Kingsmore, “An 
integrated clinico-metabolomic model improves prediction of death in 
sepsis.,” Sci. Transl. Med., vol. 5, no. 195, p. 195ra95, Jul. 2013. 
[50] D. W. Park, D. S. Kwak, Y. Y. Park, Y. Chang, J. W. Huh, C. M. Lim, 
Y. Koh, D. K. Song, and S. B. Hong, “Impact of serial measurements 
of lysophosphatidylcholine on 28-day mortality prediction in patients 
admitted to the intensive care unit with severe sepsis or septic shock,” 
75 
 
J. Crit. Care, vol. 29, no. 5, p. 882.e5-882.e11, 2014. 
[51] K. Reinhart, M. Bauer, N. C. Riedemann, and C. S. Hartog, “New 
approaches to sepsis: Molecular diagnostics and biomarkers,” Clin. 
Microbiol. Rev., vol. 25, no. 4, pp. 609–634, 2012. 
[52] D. S. DeLuca, J. Z. Levin, A. Sivachenko, T. Fennell, M.-D. Nazaire, 
C. Williams, M. Reich, W. Winckler, and G. Getz, “RNA-SeQC: RNA-
seq metrics for quality control and process optimization.,” 
Bioinformatics, vol. 28, no. 11, pp. 1530–2, Jun. 2012. 
[53] Y. Liao, G. K. Smyth, and W. Shi, “FeatureCounts: An efficient general 
purpose program for assigning sequence reads to genomic features,” 
Bioinformatics, vol. 30, no. 7, pp. 923–930, 2014. 
[54] M. I. Love, W. Huber, and S. Anders, “Moderated estimation of fold 
change and dispersion for RNA-seq data with DESeq2.,” Genome 
Biol., vol. 15, no. 12, p. 550, 2014. 
[55] D. W. Huang, R. a Lempicki, and B. T. Sherman, “Systematic and 
integrative analysis of large gene lists using DAVID bioinformatics 
resources.,” Nat. Protoc., vol. 4, no. 1, pp. 44–57, 2009. 
[56] B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of human 
genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005. 
[57] V. Agarwal, G. W. Bell, J. W. Nam, and D. P. Bartel, “Predicting 
effective microRNA target sites in mammalian mRNAs,” Elife, vol. 4, 
no. AUGUST2015, 2015. 
[58] R. C. Friedman, K. K. H. Farh, C. B. Burge, and D. P. Bartel, “Most 
mammalian mRNAs are conserved targets of microRNAs,” Genome 
Res., vol. 19, no. 1, pp. 92–105, 2009. 
[59] F. Aletti, C. Conti, M. Ferrario, V. Ribas, B. B. Pinto, A. Herpain, E. 
Post, E. R. Medina, C. Barlassina, E. De Oliveira, R. Pastorelli, G. 
Tedeschi, G. Ristagno, F. S. Taccone, G. W. Schmid-schönbein, R. 
Ferrer, D. De Backer, K. Bendjelid, and G. Baselli, “ShockOmics : 
76 
 
multiscale approach to the identification of molecular biomarkers in 
acute heart failure induced by shock,” Scand. J. Trauma. Resusc. 
Emerg. Med., vol. 24, no. 9, 2016. 
[60] E. E. Davenport, K. L. Burnham, J. Radhakrishnan, P. Humburg, P. 
Hutton, T. C. Mills, A. Rautanen, A. C. Gordon, C. Garrard, A. V. S. 
Hill, C. J. Hinds, and J. C. Knight, “Genomic landscape of the 
individual host response and outcomes in sepsis: A prospective cohort 
study,” Lancet Respir. Med., vol. 4, no. 4, pp. 259–271, 2016. 
[61] E. L. Tsalik, R. J. Langley, D. L. Dinwiddie, N. A. Miller, B. Yoo, J. C. 
van Velkinburgh, L. D. Smith, I. Thiffault, A. K. Jaehne, A. M. Valente, 
R. Henao, X. Yuan, S. W. Glickman, B. J. Rice, M. T. McClain, L. 
Carin, G. R. Corey, G. S. Ginsburg, C. B. Cairns, R. M. Otero, V. G. 
Fowler, E. P. Rivers, C. W. Woods, and S. F. Kingsmore, “An 
integrated transcriptome and expressed variant analysis of sepsis 
survival and death,” Genome Med., vol. 6, no. 11, p. 111, 2014. 
[62] H. R. Wong, N. Cvijanovich, R. Lin, G. L. Allen, N. J. Thomas, D. F. 
Willson, R. J. Freishtat, N. Anas, K. Meyer, P. a Checchia, M. Monaco, 
K. Odom, and T. P. Shanley, “Identification of pediatric septic shock 
subclasses based on genome-wide expression profiling.,” BMC Med., 
vol. 7, p. 34, Jan. 2009. 
[63] M.-A. Cazalis, A. Lepape, F. Venet, F. Frager, B. Mougin, H. Vallin, M. 
Paye, A. Pachot, and G. Monneret, “Early and dynamic changes in 
gene expression in septic shock patients : a genome-wide approach,” 
Intensive Care Med. Exp., vol. 2, no. 20, 2014. 
[64] C. C. Liew, J. Ma, H. C. Tang, R. Zheng, and A. A. Dempsey, “The 
peripheral blood transcriptome dynamically reflects system wide 
biology: A potential diagnostic tool,” J. Lab. Clin. Med., vol. 147, no. 3, 
pp. 126–132, 2006. 
[65] H. Tsujimoto, S. Ono, P. A. Efron, P. O. Scumpia, L. L. Moldawer, and 
H. Mochizuki, “Role of Toll-like receptors in the development of 
77 
 
sepsis.,” Shock, vol. 29, no. 3, pp. 315–21, 2008. 
[66] J.-C. Simard, A. Cesaro, J. Chapeton-Montes, M. Tardif, F. Antoine, 
D. Girard, and P. a Tessier, “S100A8 and S100A9 induce cytokine 
expression and regulate the NLRP3 inflammasome via ROS-
dependent activation of NF-κB(1.).,” PLoS One, vol. 8, no. 8, p. 
e72138, 2013. 
[67] C. A. Dinarello, “Interleukin-1 in the pathogenesis and treatment of 
inflammatory diseases,” Blood, vol. 117, no. 14, pp. 3720–3732, 2011. 
[68] C. A. Dinarello, “Interleukin 1 and interleukin 18 as mediators of 
inflammation and the aging process,” Am. J. Clin. Nutr., vol. 83, no. 2, 
2006. 
[69] Y. Lang, Y. Jiang, M. Gao, W. Wang, N. Wang, K. Wang, H. Zhang, 
G. Chen, K. Liu, M. Liu, M. Yang, and X. Xiao, “Interleukin-1 Receptor 
2: A New Biomarker for Sepsis Diagnosis and GramNegative/ 
GramPositive Bacterial Differentiation.,” Shock, vol. 47, no. 1, pp. 
119–124, 2017. 
[70] E. J. Giamarellos-Bourboulis and S. M. Opal, “The role of genetics and 
antibodies in sepsis.,” Ann. Transl. Med., vol. 4, no. 17, p. 328, 2016. 
[71] H. R. Wong, “Genome-wide expression profiling in pediatric septic 
shock,” Pediatr Res, vol. 73, no. 4, pp. 564–569, 2013. 
[72] B. Samuelsson, “Role of basic science in the development of new 
medicines: examples from the eicosanoid field,” J. Biol. Chem., vol. 
287, no. 13, pp. 10070–10080, 2012. 
[73] A. J. de Jong, M. Kloppenburg, R. E. M. Toes, and A. Ioan-Facsinay, 
“Fatty acids, lipid mediators, and T-cell function,” Frontiers in 
Immunology, vol. 5, no. OCT. 2014. 
[74] A. M. Gajda and J. Storch, “Enterocyte fatty acid-binding proteins 
(FABPs): Different functions of liver and intestinal FABPs in the 
intestine,” Prostaglandins Leukot. Essent. Fat. Acids, vol. 93, pp. 9–
16, 2015. 
78 
 
[75] T. Hara, I. Kimura, D. Inoue, A. Ichimura, and A. Hirasawa, “Free fatty 
acid receptors and their role in regulation of energy metabolism,” Rev. 
Physiol. Biochem. Pharmacol., vol. 159, pp. 1–77, 2013. 
[76] C. M. Ensor and H. H. Tai, “15-Hydroxyprostaglandin 
dehydrogenase,” J. Lipid Mediat. Cell Signal., vol. 12, no. 2–3, pp. 
313–319, 1995. 
[77] C. N. Serhan, “Pro-resolving lipid mediators are leads for resolution 
physiology.,” Nature, vol. 510, no. 7503, pp. 92–101, 2014. 
[78] S. K. Orr, K. L. Butler, D. Hayden, R. G. Tompkins, C. N. Serhan, and 
D. Irimia, “Gene Expression of Proresolving Lipid Mediator Pathways 
Is Associated With Clinical Outcomes in Trauma Patients,” Crit Care 
Med, vol. 43, no. 12, pp. 2642–2650, 2015. 
[79] Y. Zeng, R. H. Adamson, F.-R. E. Curry, and J. M. Tarbell, 
“Sphingosine-1-phosphate protects endothelial glycocalyx by 
inhibiting syndecan-1 shedding.,” Am. J. Physiol. Heart Circ. Physiol., 
vol. 306, no. 3, pp. H363-72, 2014. 
[80] D. De Backer, K. Donadello, Y. Sakr, G. Ospina-Tascon, D. Salgado, 
S. Scolletta, and J. L. Vincent, “Microcirculatory alterations in patients 
with severe sepsis: impact of time of assessment and relationship with 
outcome,” Crit Care Med, vol. 41, no. 3, pp. 791–799, 2013. 
[81] J. Boisramé-Helms, H. Kremer, V. Schini-Kerth, and F. Meziani, 
“Endothelial dysfunction in sepsis.,” Curr. Vasc. Pharmacol., vol. 11, 
no. 2, pp. 150–60, 2013. 
[82] N. Al-Banna and C. Lehmann, “Oxidized LDL and LOX-1 in 
experimental sepsis,” Mediators of Inflammation, vol. 2013. 2013. 
[83] J. Pravda, “Metabolic theory of septic shock.,” World J. Crit. care Med., 
vol. 3, no. 2, pp. 45–54, 2014. 
[84] C. T. N. Pham, “Neutrophil serine proteases: specific regulators of 
inflammation.,” Nat. Rev. Immunol., vol. 6, no. 7, pp. 541–50, 2006. 
[85] L. A. van Vught, P. M. C. Klein Klouwenberg, C. Spitoni, B. P. 
79 
 
Scicluna, M. A. Wiewel, J. Horn, M. J. Schultz, P. Nürnberg, M. J. M. 
Bonten, O. L. Cremer, and T. van der Poll, “Incidence, Risk Factors, 
and Attributable Mortality of Secondary Infections in the Intensive 
Care Unit After Admission for Sepsis,” Jama, vol. 315, no. 14, p. 1469, 
2016. 
[86] Z. Hu, T. Murakami, K. Suzuki, H. Tamura, J. Reich, K. Kuwahara-
Arai, T. Iba, and I. Nagaoka, “Antimicrobial cathelicidin peptide LL-37 
inhibits the pyroptosis of macrophages and improves the survival of 
polybacterial septic mice,” Int. Immunol., vol. 28, no. 5, pp. 245–253, 
2016. 
[87] A. Lauhio, J. Hästbacka, V. Pettilä, T. Tervahartiala, S. Karlsson, T. 
Varpula, M. Varpula, E. Ruokonen, T. Sorsa, and E. Kolho, “Serum 
MMP-8, -9 and TIMP-1 in sepsis: High serum levels of MMP-8 and 
TIMP-1 are associated with fatal outcome in a multicentre, prospective 
cohort study. Hypothetical impact of tetracyclines,” Pharmacol. Res., 
vol. 64, no. 6, pp. 590–594, 2011. 
[88] W. C. Parks, C. L. Wilson, and Y. S. Lopez-Boado, “Matrix 
metalloproteinases as modulators of inflammation and Innate 
Immunity,” Nat. Rev. Immunol., vol. 4, no. 8, pp. 617–29, 2004. 
[89] J. J. Cena, M. M. Lalu, W. J. Cho, A. K. Chow, M. L. Bagdan, E. E. 
Daniel, M. M. Castro, and R. Schulz, “Inhibition of matrix 
metalloproteinase activity in vivo protects against vascular 
hyporeactivity in endotoxemia.,” Am. J. Physiol. Heart Circ. Physiol., 
vol. 298, no. 1, pp. H45–H51, 2010. 
[90] A. Bayés-Genís, J. Barallat, D. Pascual, J. Nuñez, G. Miñana, J. 
Sánchez-Mas, A. Galan, J. Sanchis, E. Zamora, M. T. Pérez-Martínez, 
and J. Lupón, “Prognostic Value and Kinetics of Soluble Neprilysin in 
Acute Heart Failure. A Pilot Study.,” JACC Hear. Fail., vol. 3, no. 8, 
pp. 641–644, 2015. 
[91] G. Cesarman-Maus and K. A. Hajjar, “Molecular mechanisms of 
80 
 
fibrinolysis,” Br. J. Haematol., vol. 129, no. 3, pp. 307–321, 2005. 
[92] A. Stempien-Otero, A. Plawman, J. Meznarich, T. Dyamenahalli, G. 
Otsuka, and D. A. Dichek, “Mechanisms of cardiac fibrosis induced by 
urokinase plasminogen activator,” J. Biol. Chem., vol. 281, no. 22, pp. 
15345–15351, 2006. 
[93] Y. Borne, M. Persson, O. Melander, J. G. Smith, and G. Engstrom, 
“Increased plasma level of soluble urokinase plasminogen activator 
receptor is associated with incidence of heart failure but not atrial 
fibrillation,” Eur J Hear. Fail, vol. 16, no. 4, pp. 377–383, 2014. 
[94] R. Sharony, P.-J. Yu, J. Park, A. C. Galloway, P. Mignatti, and G. 
Pintucci, “Protein targets of inflammatory serine proteases and 
cardiovascular disease.,” J. Inflamm., vol. 7, no. 1, p. 45, 2010. 
[95] G. W. Schmid-Shönbein, “Inflammation and the Autodigestive 
Hypothesis,” Microcirculation, vol. 16, no. 4, pp. 289–306, 2010. 
[96] T. C. Vary and S. R. Kimball, “Sepsis-Induced Changes in Protein 
Synthesis: Differential Effects on Fast- and Slow-Twitch Muscles,” 
Am. J. Physiol., vol. 262, no. 6, pp. C1513–C1519, 1992. 
[97] G. F. Lehner, U. Harler, V. M. Haller, C. Feistritzer, J. Hasslacher, S. 
Dunzendorfer, R. Bellmann, and M. Joannidis, “Characterization of 
Microvesicles in Septic Shock Using High-Sensitivity Flow 
Cytometry.,” Shock, vol. 46, no. 4, pp. 373–381, 2016. 
[98] Y. Ma, D. Vilanova, K. Atalar, O. Delfour, J. Edgeworth, M. Ostermann, 
M. Hernandez-Fuentes, S. Razafimahatratra, B. Michot, D. H. 
Persing, I. Ziegler, B. Törös, P. Mölling, P. Olcén, R. Beale, and G. M. 
Lord, “Genome-Wide Sequencing of Cellular microRNAs Identifies a 
Combinatorial Expression Signature Diagnostic of Sepsis,” PLoS One, 
vol. 8, no. 10, 2013. 
[99] J. T. Y. Kung, D. Colognori, and J. T. Lee, “Long noncoding RNAs: 
Past, present, and future,” Genetics, vol. 193, no. 3. pp. 651–669, 
2013. 
81 
 
[100] K. C. Wang and H. Y. Chang, “Molecular Mechanisms of Long 
Noncoding RNAs,” Molecular Cell, vol. 43, no. 6. pp. 904–914, 2011. 
[101] X. Zhu, Y. Yuan, and S. Rao, “LncRNA MIAT enhances cardiac 
hypertrophy partly through sponging miR-150,” Eur. Rev. Med. 
Pharmacol. Sci., vol. 20, pp. 3653–3660, 2016. 
[102] S. Akira and K. Takeda, “Toll-like receptor signalling.,” Nat. Rev. 
Immunol., vol. 4, no. 7, pp. 499–511, 2004. 
[103] T. Zarubin and J. Han, “Activation and signaling of the p38 MAP kinase 
pathway.,” Cell Res., vol. 15, no. 1, pp. 11–18, 2005. 
[104] Y. Vasquez, C. H. Williams, and R. M. Hardaway, “Effect of urokinase 
on disseminated intravascular coagulation,” J. Appl. Physiol., vol. 85, 
no. 4, pp. 1421–1428, 1998. 
 
 
 
 
 
82 
 
8 APPENDIX 
 
Table 13 List of genes in each GO term resulted significantly enriched in the overrepresentation analysis. 
Gene Ontology Genes
GO:0038096:Fc-gamma receptor signaling pathway involved in phagocytosis
IGHG1, IGHG2, IGHG3, IGHG4, FGR, IGHV3-48, IGKV1-17, CD247, ARPC4, ABI1, ARPC5, ACTR3, ACTR2, CDC42, ARPC3, ARPC2, FCGR1A, IGHV3-
23, PIK3CA, IGKC, SYK, IGLV1-51, CD3G, HCK, NCKAP1L, ELMO2, ARPC1A, IGHV3-30, ARPC1B, IGKV1-5, MYO10, IGHV3-7, IGHV4-39, IGHV3-33, 
GO:0038095:Fc-epsilon receptor signaling pathway
IGHV3-48, IGKV1-17, NFKBIA, NFKB1, BTK, PSMB6, PSMB3, MAP3K1, IGHV3-23, PSMD1, PIK3CA, FCER1G, PSMD5, IGKC, NFATC2, PSMD6, 
FBXW11, PSMD7, CHUK, RPS27A, SYK, FCER1A, ITK, IGLV1-51, IGHV3-30, NRAS, CARD11, IGKV1-5, PSMC6, IGHV3-7, LAT2, IGHV4-39, IGHV3-
33, PSMA6, PLCG1, PSMD12, PSMD10, PSMC1, IGLV7-43, IGKV4-1, IGKV3-20, IGLC2, IGLC3
GO:0045087:innate immune response
IGHG1, IGHG2, IGHG3, IGHG4, S100A8, TBK1, CAPZA2, CAPZA1, PPARG, S100A9, TLR1, TLR2, TLR4, NFKB1, TLR5, IGHM, FES, TLR7, LGR4, 
TLR8, BTK, MARCO, NLRC4, MAP3K5, SH2D1A, NOD2, CLEC4E, CD46, LILRA5, IL1RAP, VNN1, CLEC4D, RPS27A, CHUK, SYK, MATK, F12, LY96, 
CAMP, GZMM, C1QB, KLRG1, MB21D1, DEFA4, TRIM32, LCK, DEFA3, SLPI, NAIP, CD300LB, CD244, HMGB2, FGR, JCHAIN, MAP4K2, TRDC, 
IRAK4, SERINC5, REL, IGHV3-23, IGHA1, ZAP70, IGHA2, FCER1G, CLEC6A, MR1, IGKC, PTX3, CD6, TRAF3, ITK, CR1, TRIM28, BMX, ANXA1, 
GO:0042742:defense response to bacterium
IGHG1, IGHG2, IGHG3, IGHG4, S100A8, TLR1, S100A9, HP, TLR4, TRDC, TLR5, IL10, RAB1A, NLRC4, NOD2, CLEC4E, IGHV3-23, FCER1G, 
CLEC4D, IGKC, SPN, SYK, CEBPB, CEBPE, CAMP, ELANE, LYZ, ANXA3, S100A12, PLAC8, DEFA3, MPO, RBPJ, IGLC2, IGLC3
GO:0002755:MyD88-dependent toll-like receptor signaling pathway IRAK4, IRAK3, LY96, MAP3K1, TLR1, TLR2, TLR4, TLR5, TLR7, RPS27A, TLR8, BTK
GO:0002223:stimulatory C-type lectin receptor signaling pathway
NFKBIA, NFKB1, RPS6KA5, CARD11, NRAS, PSMC6, PSMB6, PSMD12, PSMA6, CLEC4E, PSMD10, PSMB3, PSMD1, PSMC1, FCER1G, CLEC6A, 
CLEC4D, PSMD5, PSMD6, PSMD7, FBXW11, CHUK, RPS27A, SYK
GO:0002250:adaptive immune response
GPR183, CD244, CD8B, JCHAIN, IGHM, SKAP1, BTK, SH2D1A, CD46, FCGR1B, LILRA6, ZAP70, ERAP1, CD4, CLEC6A, CLEC4D, CD6, PAG1, 
SYK, ITK, DBNL, LAIR1, CRTAM, ADGRE1, SIT1, THEMIS, ANXA1, CD1C, EOMES, TNFRSF17, TRAT1, CTSL, LAT2, BTN3A1, CD86, CAMK4, 
GO:0050853:B cell receptor signaling pathway
MEF2C, IGHG1, IGHG2, IGHG3, IGHG4, TRDC, IGHM, BTK, KLHL6, BCL2, IGHV3-23, ZAP70, IGHA1, IGHA2, IGKC, NFATC2, SYK, PTPRC, 
NCKAP1L, CD38, LAT2, LCK, IGLC2, IGLC3, PLEKHA1
GO:0050852:T cell receptor signaling pathway
CD247, NFKBIA, PTPN22, NFKB1, SKAP1, PTEN, TRAC, PSMB6, PSMB3, PDE4B, PSMD1, ZAP70, PIK3CA, CD4, PSMD5, PSMD6, PSMD7, 
FBXW11, CHUK, RPS27A, PAG1, CD28, ITK, PTPRC, CD3G, CD3D, THEMIS, PDE4D, TRBC1, TRAT1, CARD11, BTN3A1, PSMC6, PSMA6, PLCG1, 
GO:0050871:positive regulation of B cell activation IGHG1, IGHG2, IGHG3, IGHG4, TRDC, IGHM, NOD2, IGHV3-23, IGHA1, IGHA2, IGKC, TNIP2, IGLC2, IGLC3
GO:0031295:T cell costimulation
CD3G, CD3D, LGALS1, CD247, TRBC1, CDC42, CARD11, CD86, TRAC, TNFSF13B, ICOS, LCK, MAP3K8, PIK3CA, CD4, MAP3K14, CD5, DPP4, 
SPN, CD28
GO:0042110:T cell activation ITK, CD3G, CD8A, CD8B, AZI2, HSH2D, CD86, NLRC3, NEDD4, RAB29, ZAP70, CD2, IRF4, DPP4
GO:0030217:T cell differentiation PTPRC, PKNOX1, CD3D, PTPN2, LCK, ZAP70, PTPN22, CD4, KIT, IL7R, RUNX2
GO:0006955:immune response
AQP9, CD8A, IGHV3-48, CD8B, IGKV1-17, TLR1, TLR2, TLR4, HLA-DMB, VIPR1, HLA-DMA, TLR7, IL10, CD96, LTB4R, COL4A3BP, S1PR4, IL4R, 
CEACAM8, IL1RAP, SPN, CHUK, CIITA, IGLV1-51, IL18RAP, GZMA, TRBC1, CD164, GZMH, OSM, TNFRSF9, CD86, IGKV1-5, TNFSF13B, CST7, 
LAX1, IGLV7-43, SLPI, IGKV4-1, MAP3K14, PTGDR2, CTSG, IL1R2, GPR183, IGHV1-2, TNFRSF25, ENPP2, CYSLTR2, CCR1, JCHAIN, GPR65, 
MAP4K2, IL32, IL7R, CD74, IL10RB, ICOS, FCGR1A, FCGR1B, IGHV3-23, CNR2, IGHA1, ZAP70, IGHA2, CD4, MR1, IGKC, THBS1, CD27, IL18R1, 
GO:0050776:regulation of immune response
IFITM1, CD8A, CD8B, IGHV3-48, IGKV1-17, CD247, SIGLEC9, CD96, SH2D1A, TRAC, FCGR1A, ITGB7, OSCAR, IGHV3-23, CLEC2D, IGKC, KLRB1, 
LAIR1, CRTAM, IGLV1-51, CD3G, CD3D, SELL, ICAM5, CD1C, CD160, NECTIN2, SPPL2A, ITGA4, TRBC1, IGHV3-30, CARD11, IGKV1-5, IGHV3-7, 
IGHV4-39, IGHV3-33, IGLV7-43, CD300LF, IGKV4-1, IGKV3-20, IGLC2, CD300LB, IGLC3, CD300LD
GO:0007249:I-kappaB kinase/NF-kappaB signaling ROCK1, HACD3, LY96, TBK1, TIFA, NFKB1, TLR4, BIRC3, AZI2, TANK, TLR8, BTK, NLRC3, REL, RIPK3, MAP3K14, TNIP2, RPS27A, CHUK
GO:0006954:inflammatory response
PTGS2, S100A8, TBK1, S100A9, TLR1, TLR2, TLR4, NFKB1, TLR5, TLR7, IL10, TLR8, S1PR3, NLRC4, CXCR4, LTB4R, CXCR6, IL1RAP, VNN1, TNIP2, 
CHUK, SYK, CIITA, PTGER2, HYAL3, SP100, IL18RAP, LY96, LYZ, TNFRSF9, PROK2, ALOX15, KLRG1, CAMK4, CCR3, NAIP, NMI, TNFRSF25, 
FFAR3, CCR1, FPR1, KIT, FPR2, AZU1, REL, IL10RB, CNR2, ZAP70, PTX3, THBS1, CD27, CEBPB, OLR1, HCK, CHI3L1, ANXA1, PLGRKT, S100A12, 
GO:0050900:leukocyte migration
CD244, MMP9, FPR1, FPR2, ITGAM, CD74, CD44, CD177, PDE4B, CEACAM8, CD2, CEACAM6, PIK3CA, FCER1G, CEACAM1, SPN, OLR1, ROCK1, 
SELL, ELANE, ITGA4, SLC16A3, NRAS, PLCG1, CD58, LCK, MERTK
GO:0000502:proteasome complex RAD23B, KIAA0368, UBR1, PSMC6, PSMB6, PSMD12, VCP, PSMA6, PSMD10, PSMB3, PSMD1, PSMC1, PSMD5, PSMD6, PSMD7
GO:0004175:endopeptidase activity TRABD2A, MMP9, APH1B, ELANE, MME, SENP2, PSMB6, PSMA6, PARL, TMEM59, CD46, PSMD1, ERAP1, HTRA3, ADAMTS3
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Table 14 List of genes in each GO term resulted significantly enriched in the overrepresentation analysis. 
 
 
 
Gene Ontology Genes
GO:0070062:extracellular exosome
LDHB, LDHA, RPL14, RP2, PGD, IGHM, CTNNB1, OSCAR, VNN1, CAB39, DDAH2, GNG5, ADAM9, RAB27A, GLTP, RETN, RPS18, IGKV1-5, MGAM, 
RYR2, ARL8A, ARL8B, ZNHIT6, ADAMTS3, OSTF1, AHCY, GNAI3, DAAM2, HADHB, ARG1, FGL2, UBASH3A, RPS20, IGKC, RPSA, PTGR1, TAOK1, 
UPB1, UBE2L3, RPS5, RPS8, SYNE2, PI3, MCPH1, PCNA, TGFBR3, H3F3B, GK, DPP3, MARCKSL1, MTHFD1, MSRA, SMPDL3A, CEACAM8, 
DPP7, CEACAM1, DPP4, STX3, ELANE, TTC38, SDK1, LYZ, NECTIN2, ERLIN2, CLIC1, FLNB, NAPRT, CARD11, GNAQ, GNB2, TXN, SERPINB1, 
ALPL, SORD, JCHAIN, ABI1, ITM2C, ITM2A, NUMA1, UEVLD, PPP2CA, TBC1D4, ACSL4, VTA1, RPL26, TRIM23, TMEM2, PLSCR1, NRAS, IGHV3-7, 
RPL23, RPL22, GNG10, HIST1H2AH, SPG11, IGLC2, HPGD, CMTM6, ORM2, DNM2, SRP14, ATP6AP1, CAPZA2, CAPZA1, KIAA1324, SNRPD2, 
IQGAP1, PRKAR2A, FAM49B, SLC2A5, DDX23, SLC2A3, RALB, RNF149, ZNF445, RPS27A, NCALD, PATJ, PCOLCE2, ARPC1A, ARPC1B, FGR, 
ARPC4, ARPC5, ARPC3, ARPC2, RPL3, HIST1H4E, RPL5, RPL4, RPL10A, B4GALT5, RAB8B, FIBP, SPPL2A, RPL23A, MYL12B, MYL12A, LAMP1, 
LYVE1, VCP, PTTG1IP, HDHD2, HIST1H3F, CYB5R1, IMPA1, FIGNL1, IGKV1-17, HP, PRDX3, SYNGR2, HLA-DMA, RPS3, SLC1A4, CDC42, SNTB2, 
CDK5RAP2, RHOG, IMPDH2, SIT1, SPINT1, STXBP3, RPS4X, NCOA3, LCK, CA4, SNX12, UGP2, LCP1, GALNT3, CD101, GALNT2, SNX18, FKBP5, 
VIM, GALNT4, BTN2A2, CDH6, IARS, ALDH1A1, ZBTB8OS, ATIC, LRG1, TOR1A, HSPA6, TOR1B, HSPA7, VPS35, PLP2, TMC8, PDCD10, SLC12A2, 
OLR1, RNASE3, KL, ANXA1, GYG1, ANXA5, MAN1C1, FBL, ANXA3, AKR1B1, APAF1, GCA, VPS25, CADM4, S100A8, IL6ST, FAM20A, RAB3GAP1, 
S100A9, PPCS, GGT1, CD53, RAB1A, DNASE1L1, GOT2, CD44, DDX11, IFT20, CD46, RAB29, LILRA5, ERAP1, F12, DBNL, C1GALT1C1, SLC12A9, 
SUCLG1, DCTN2, PGM2, C1QB, CD38, RAB18, CAMK4, ALOX15B, TACSTD2, TXNDC5, VSIG4, TPST2, MME, EPHB4, CD74, CDC37, EPHB1, 
SERINC5, STX12, SERINC1, IGHV3-23, IDH2, ZMPSTE24, ST6GAL1, LAMTOR3, LGALS1, CHI3L1, NCKAP1L, LGALS8, CD63, PPA2, CD55, IGHV3-
33, CD59, CD58, SLC46A3, PLAU, IGHG1, IGHG2, IGHG3, IGHG4, MYO7B, FERMT3, ACTR3, ACTR2, DNAJC13, CAP1, RAB6A, DOCK10, FAM129A, 
KCNMA1, CAMP, FLOT1, ATP6V1C1, EEF1A1P5, RAB5A, MTAP, SLC27A2, YWHAZ, FUT8, PRTN3, TFG, HPRT1, AZU1, IL10RB, CD177, PCMT1, 
THBS1, QSOX1, CD27, RAB2A, PSMD12, PYGL, MAPK14, ATP6V1E1, CAPG, IGKV3-20, FCGR2A, PGK1, TSPO, CHMP4C, NIT2, MMP9, NANS, 
TIAM2, PDGFC, SPN, NQO2, CUTA, IGLV1-51, MFGE8, LYPLA1, BASP1, PPP1CB, GNS, LAT2, PSMA6, DEFA3, CPD, SLC38A1, SEPT7, MVP, 
MYL6, SRI, WNT5B, ITGB4, NEDD8, NAPB, SNX3, LMAN2, LMAN1, ITGAM, CHMP2B, PEF1, GALM, PSMB6, ITGB7, PSMB3, BLOC1S1, GALC, 
GO:0006888:ER to Golgi vesicle-mediated transport
COPA, DYNC1LI2, ARFGAP3, SEC24A, VAPA, ATL3, DYNC2LI1, LMAN2, LMAN1, RAB1A, COPB2, DDHD2, COPB1, RAB29, TGFA, SEC22B, 
SEC22C, SAR1B, RAB2A, SEC23A, DCTN6, VTI1A, BCAP31, DCTN2, COPG2, CD55, VCP, TRAPPC8, CD59, CNIH4, KLHL12, GOSR2, SEC23B
GO:0048208:COPII vesicle coating
SEC23A, PPP6C, SEC24A, TFG, PPP6R3, LMAN1, RAB1A, TRAPPC6A, SCFD1, ANKRD28, CD59, TRAPPC6B, TGFA, KLHL12, SEC22B, GOSR2, 
SAR1B
GO:0072562:blood microparticle
IGHG1, IGHG2, YWHAZ, IGHG3, IGHG4, IGKV1-17, JCHAIN, HP, HSPA1B, TRDC, IGHM, IGHV3-23, IGHA1, HSPA6, IGHA2, HSPA7, IGKC, CLIC1, 
DNPEP, STOM, C1QB, IGKV1-5, IGKV4-1, IGKV3-20, IGLC2, ORM2, IGLC3
GO:0006614:SRP-dependent cotranslational protein targeting to membrane
RPL18, SRP14, RPL19, RPL14, RPL35, RPS3, RPL6, RPL3, RPL5, RPL4, RPL10A, RPS20, RPS23, RPS27A, RPSA, SRP54, RPL26, RPL23A, 
SRPRB, RPS4X, RPS6, RPS5, RPS8, RPS18, RPL23, RPL18A, RPL13A, RPL22
GO:0006364:rRNA processing
RPL18, RNASEL, RPL19, RPL14, RPL35, NOB1, BMS1, RPS3, ISG20, WDR75, IMP3, RPL6, RPL3, RPL5, RPL4, RPL10A, RPS20, RPS27A, RPS23, 
NOL6, RPSA, EXOSC4, RPL26, RPL23A, LAS1L, HEATR1, DIEXF, DIS3L, RPS4X, RPS6, RPS5, FBL, RPS8, RPS18, RPL18A, RPL23, RPL22, 
GO:0015935:small ribosomal subunit RPSA, RPS18, IMP3, MRPS6, RPS20, RPS4X, RPS6, RPS5, RPS27A, RPS23, RPS3
GO:0022625:cytosolic large ribosomal subunit RPL18, RPL19, RPL14, COA1, RPL26, RPL35, RPL23A, RPL23, RPL18A, RPL6, RPL13A, RPL22, RPL3, RPL5, RPL4, RPL10A
GO:0006413:translational initiation
RPL18, EIF4E3, RPL19, RPL14, RPL35, RPS3, RPL6, RPL3, EIF3L, RPL5, RPL4, RPS20, RPL10A, RPS23, RPS27A, ABCE1, RPSA, RPL26, 
RPL23A, RPS4X, RPS6, RPS5, RPS8, RPS18, RPL23, RPL18A, RPL13A, RPL22
GO:0003735:structural constituent of ribosome
RPL18, MRPS33, RPL19, RPL14, COA1, RPL35, MRPS31, MRPS30, RPS3, SLC25A20, IMP3, SLC25A24, RPL6, RPL3, SLC25A28, RPL5, RPL4, 
RPL10A, RPS20, SLC25A40, RPS23, RPS27A, RPSA, MRPS25, RPL26, RPL23A, MRPS6, RPS4X, RPS6, RPS5, RPS8, SLC25A11, RPS18, 
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